UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10−Q

 

(Mark One)

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: March 31, 2023

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ____________ to _____________

 

Commission File Number: 001-41290

 

SMART FOR LIFE, INC.

(Exact name of registrant as specified in its charter)

   

Nevada		81-5360128
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

 

990 S Rogers Circle, Suite 3, Boca Raton, FL		33487
(Address of principal executive offices)		(Zip Code)

 

(786) 749-1221

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		SMFL		The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐		Accelerated filer ☐
Non-accelerated filer ☒		Smaller reporting company ☒
		Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for comply with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐ No ☒

 

As of May 12, 2023, there were 1,420,114 shares of the registrant’s common stock issued and outstanding.

 

 

 

Smart for Life, Inc.

 

Quarterly Report on Form 10-Q

 Period Ended March 31, 2023

 

TABLE OF CONTENTS 

 

PART I
FINANCIAL INFORMATION
Item 1.	Financial Statements (unaudited)	1
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	27
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	39
Item 4.	Controls and Procedures	39
PART II
OTHER INFORMATION
Item 1.	Legal Proceedings	40
Item 1A.	Risk Factors	40
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	40
Item 3.	Defaults Upon Senior Securities	40
Item 4.	Mine Safety Disclosures	40
Item 5.	Other Information	40
Item 6.	Exhibits	41

 

 

PART I

FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS.

 

SMART FOR LIFE, INC.

UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

		Page
Condensed Consolidated Balance Sheets as of March 31, 2023 (unaudited) and December 31, 2022		2
Condensed Consolidated Statements of Operations for the Three Months ended March 31, 2023 and 2022 (unaudited)		3
Condensed Consolidated Statement of Changes in Stockholders’ Equity (deficit) for the Three Months ended March 31, 2023 and 2022 (unaudited)		4
Condensed Consolidated Statements of Cash Flows for the Three Months ended March 31, 2023 and 2022 (unaudited)		5
Notes to Unaudited Condensed Consolidated Financial Statements		6

 

 

SMART FOR LIFE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
MARCH 31, 2023 AND DECEMBER 31, 2022

 

		March 31, 2023				December 31, 2022
		(unaudited)
ASSETS
Current assets:
Cash		$	86,194			$	69,714
Accounts receivable, net			278,745				561,894
Inventory			2,095,212				2,665,501
Prepaid expenses and other current assets			318,109				306,867
Total current assets			2,778,260				3,603,976
Property and equipment, net			401,227				482,219
Intangible assets, net			20,326,040				20,936,258
Goodwill			1,342,000				1,342,000
Deposits			114,062				109,638
Operating lease right-of-use assets			2,590,839				2,672,866
Total other assets			24,774,168				25,542,981
Total assets		$	27,552,428			$	29,146,957
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable		$	4,809,102			$	4,123,837
Accrued expenses			2,501,223				1,888,013
Accrued expenses, related parties			1,127,194				947,951
Due to related parties, net			12,700				—
Deferred revenue			770,777				662,879
Preferred stock dividends payable			600,750				600,750
Operating lease liability, current			317,606				303,819
Debt, current, net of debt discounts			7,870,185				6,616,273
Total current liabilities			18,009,537				15,143,522
Long-term liabilities:
Operating lease liability, noncurrent			2,337,617				2,423,446
Debt, noncurrent			13,798,981				13,941,973
Total long-term liabilities			16,136,598				16,365,419
Total liabilities			34,146,135				31,508,941
Commitments and contingencies
Stockholders’ Deficit
Preferred Stock, $.0001 par value, 10,000,000 shares authorized and 1,000 shares outstanding as of March 31, 2023 and December 2022			—				—
Series A Convertible Preferred Stock, $.0001 par value, 8,000 shares authorized and 1,000 shares issued and outstanding as of March 31, 2023 and December 2022			—				—
Common Stock, $.0001 par value, 500,000,000 shares authorized, 797,054 and 735,559 issued and outstanding as of March 31, 2023 and December 2022, respectively			79				73
Additional paid in capital			42,682,944				42,630,358
Accumulated deficit			(49,276,730	)			(44,992,415	)
Total stockholders’ deficit			(6,593,707	)			(2,361,984	)
Total liabilities and stockholders’ deficit		$	27,552,428			$	29,146,957

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

 

 

SMART FOR LIFE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(UNAUDITED)

 

		March 31, 2023				March 31, 2022
Revenues
Products		$	2,059,712			$	3,575,459
Advertising			344,855				879,427
Total revenues			2,404,567				4,454,886
Cost of revenues
Products			1,307,444				2,297,010
Advertising			269,394				640,313
Total cost of revenues			1,576,838				2,937,323
Gross profit			827,729				1,517,563
Operating expenses
General and administrative			1,095,207				1,721,855
Compensation - administrative			1,472,374				2,003,835
Professional services			303,996				640,731
Consulting fees – related parties			27,547				—
Depreciation and amortization expense			691,210				423,010
Total operating expenses			3,590,334				4,789,431
Operating loss			(2,762,605	)			(3,271,868	)
Other income (expenses)
Other income (expense)			23,152				(506,133	)
Change in fair value of derivative liability			—				(38,997	)
Interest expense			(1,544,862	)			(12,757,479	)
Total other expenses			(1,521,710	)			(13,302,609	)
Loss before income taxes			(4,284,315	)			(16,574,477	)
Income tax expense			—				—
Net loss		$	(4,284,315	)		$	(16,574,477	)
Series A preferred stock dividends			—				(85,417	)
Net loss attributable to common shareholders			(4,284,315	)			(16,659,894	)
Loss per share basic and diluted		$	(5.43	)		$	(41.06	)
Weighted average shares outstanding			788,171				405,754

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

 

 

SMART FOR LIFE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)
FOR THE THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(UNAUDITED)

 

For the Three Months Ended March 31, 2023

 

		Preferred Stock								Common Stock								Additional Paid-In				Accumulated
		Shares				Amount				Shares				Amount				Capital				Deficit				Total
Balance, January 1, 2023			1,000			$	—				735,559			$	73			$	42,630,358			$	(44,992,415	)		$	(2,361,984	)
Exercise of warrants			—				—				61,495				6				113				—				119
Stock-based compensation			—				—				—				—				52,473				—				52,473
Net loss			—				—				—				—				—				(4,284,315	)			(4,284,315	)
Balance, March 31, 2023			1,000				—				797,054			$	79			$	42,682,944			$	(49,276,730	)		$	(6,593,707	)

 

For the Three Months Ended March 31, 2022

 

		Preferred Stock								Common Stock								Additional Paid-In				Accumulated
		Shares				Amount				Shares				Amount				Capital				Deficit				Total
Balance, January 1, 2022			8,000			$	1				278,750			$	1,394			$	8,922,467			$	(15,014,600	)		$	(6,090,738	)
Stock issued for cash with initial public offering			—				—				28,800				144				10,623,348				—				10,623,348
Series A warrants issued in connection with initial public offering			—				—				—				—				1,902,689				—				1,902,689
Series B warrants in connection with initial public offering			—				—				—				—				158,558				—				158,558
Warrants issued in connection with debt			—				—				—				—				65,624				—				65,624
Stock issued upon exercise of Series B Warrants			—				—				28,755				144				(144	)			—				—
Stock issued upon conversion of convertible notes			—				—				24,790				124				5,622,761				—				5,622,885
Stock issued in connection with acquisition			—				—				850				4				(4	)			—				—
Stock issued for conversion of accounts payable			—				—				294				1				147,222				—				147,223
Stock issued for services			—				—				17,540				88				822,538				—				822,626
Stock issued upon conversion of preferred stock			(7,000	)			(1	)			209,989				1,050				(1,049	)			—				—
Common stock issued under debt agreements			—				—				43,380				217				10,844,743				—				10,844,960
Preferred stock dividend payable			—				—				—				—				(85,417	)			—				(85,417	)
Net loss			—				—				—				—				—				(16,574,477	)			(16,574,477	)
Balance, March 31, 2022			1,000			$	—				633,148			$	3,166			$	39,023,336			$	(31,589,077	)		$	7,437,425

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

 

 

SMART FOR LIFE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(UNAUDITED)

 

		March 31, 2023				March 31, 2022
Cash flows from operating activities:
Net loss		$	(4,284,315	)		$	(16,574,477	)
Adjustments to reconcile net loss to net cash used in operating activities:
Debt issuance cost			728,544				516,458
Depreciation and amortization expense			691,210				423,010
Stock-based compensation			52,473				822,626
Interest expense associated with warrants issued with debt			—				65,624
Interest expense associated to discounts on debt obtained			—				79,412
Interest expense associated with debt agreements			—				10,844,961
Non-cash operating lease costs, net			9,985				(123,209	)
Change in value of derivative liability			—				312,724
Changes in operating assets and liabilities:
Accounts receivable, net			283,149				(175,465	)
Inventory			570,289				(656,953	)
Prepaid expenses and other current assets			(11,242	)			(47,724	)
Deposits and other assets			(4,424	)			—
Accounts payable			685,265				176,620
Accrued expenses			613,210				(459,056	)
Accrued expenses, related parties			179,243				344,713
Deferred revenue			107,898				238,534
Net cash used in operating activities			(378,715	)			(4,212,202	)
Cash flows from investing activities:
Additions to property and equipment			—				(15,963	)
Net cash used in investing activities			—				(15,963	)
Cash flows from financing activities:
Receipts from related parties			12,700				344,873
Payments to related parties			—				(1,314,382	)
Proceeds from initial public offering			—				12,738,288
Proceeds from exercise of warrants			119				—
Proceeds from debt			1,409,000				783,738
Repayments on debt			(1,026,624	)			(6,924,841	)
Payment of fees from issuance of common stock			—				(53,549	)
Net cash provided by financing activities			395,195				5,574,127
Net increase in cash			16,480				1,345,962
Cash, beginning of period			69,714				205,093
Cash, end of period		$	86,194			$	1,551,055
Supplemental disclosure of cash flow information:
Interest paid		$	1,447,249			$	883,974
Non-cash investing and financing activities:
Stock issued for conversion of accounts payable		$	—			$	147,223
Debt issuance cost in connection with debt		$	333,664			$	—
Stock issued for conversion of convertible notes and interest		$	—			$	5,622,885

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

 

 

SMART FOR LIFE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(UNAUDITED)

 

Note 1 — Description of Business

 

Smart for Life, Inc., formerly Bonne Santé Group, Inc. (“SMFL”), is a Nevada corporation which was formed on February 2, 2017. Structured as a global holding company, it is engaged in the development, marketing, manufacturing, acquisition, operation and sale of a broad spectrum of nutraceutical and related products with an emphasis on Health & Wellness.

 

On March 8, 2018, SMFL acquired 51% of Millenium Natural Manufacturing Corp. and Millenium Natural Health Products, Inc. On October 8, 2019, SMFL entered into an agreement to acquire the remaining 49% of these companies, subject to certain conditions which were subsequently met. On September 30, 2020, the name of Millenium Natural Manufacturing Corp. was changed to Bonne Sante Natural Manufacturing, Inc. (“BSNM”), and on November 24, 2020, Millenium Natural Health Products Inc. was merged into BSNM. Based in Doral, Florida, BSNM operates a 22,000 square-foot FDA-certified manufacturing facility. It manufactures nutritional products for a significant number of customers.

 

On July 1, 2021, SMFL acquired 100% of Doctors Scientific Organica, LLC d/b/a Smart for Life, Oyster Management Services, Ltd., Lawee Enterprises, L.L.C. and U.S. Medical Care Holdings, L.L.C. On August 27, 2021, SMFL transferred all of the equity interests of Oyster Management Services, Ltd., Lawee Enterprises, L.L.C. and U.S. Medical Care Holdings, L.L.C. to Doctors Scientific Organica, LLC. On May 19, 2022, SMFL acquired 100% of Lavi Enterprises, LLC. On the same date, SMFL transferred all of the equity interests of Lavi Enterprises, LLC to Doctors Scientific Organica, LLC. On December 13, 2022, Oyster Management Services, Ltd. was converted to a limited liability company known as Oyster Management Services, L.L.C. As a result of the foregoing, Oyster Management Services, L.L.C., Lawee Enterprises, L.L.C., U.S. Medical Care Holdings, L.L.C. and Lavi Enterprises, LLC are now wholly owned subsidiaries of Doctors Scientific Organica, LLC (collectively, “DSO”). Based in Riviera Beach, Florida, DSO operates a 30,000 square-foot FDA-certified manufacturing facility. DSO manufactures and sells weight management foods and related products. Additionally, DSO provides manufacturing services for other customers.

 

On August 24, 2021, Smart for Life Canada Inc. (“DSO Canada”) was established as a wholly owned subsidiary of Doctors Scientific Organica, LLC in Canada. SMFL Canada sells retail products through a retail store location in Montreal Canada and the same location also acts as distribution center for international direct to consumer and big box customers. It maintains inventory and employees at this location.

 

On November 8, 2021, SMFL acquired 100% of Nexus Offers, Inc. (“Nexus”). Nexus is a network platform in the affiliate marketing space. Affiliate marketing is an advertising model in which a product vendor compensates third-party digital marketers to generate traffic or leads for the product vendor’s products and services. The third-party digital marketers are referred to as affiliates, and the commission fee incentivizes them to find ways to promote the products being sold by the product vendor. Based in Miami, Florida, Nexus operates virtually.

 

On December 6, 2021, SMFL acquired 100% of GSP Nutrition Inc. (“GSP”). GSP is a sports nutrition company that offers nutritional supplements for athletes and active lifestyle consumers under the Sports Illustrated Nutrition brand. Based in Miami, Florida, GSP operates virtually. 

 

On July 29, 2022, SMFL acquired 100% of Ceautamed Worldwide, LLC and its wholly-owned subsidiaries Wellness Watchers Global, LLC and Greens First Female LLC (collectively, “Ceautamed”). Ceautamed is based in Boca Raton, Florida and owns the Greens First line of branded products which have been specifically marketed to the healthcare provider sector. 

 

On August 15, 2022, SMFL entered into a joint venture with a seller of Ceautamed to form Smart Acquisition Group, LLC. This subsidiary is 50% owned by the Company and 50% owned by Stuart Benson, the former owner and principal of Ceautamed. This company was formed to expand M&A growth initiatives through the identification, negotiation, financing and acquisition of companies by SMFL.

 

Note 2 — Summary of Significant Accounting Policies

  

Principles of Consolidation

 

The condensed consolidated financial statements reflect the consolidated operations of SMFL and its wholly owned subsidiaries BSNM, DSO, DSO Canada, Nexus, GSP, and Ceautamed (collectively the “Company”) and are prepared in the United States Dollars in accordance with generally accepted accounting principles in the United States of America (“GAAP”). Intercompany balances and transactions have been eliminated in consolidation.

 

 

SMART FOR LIFE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(UNAUDITED)

 

Basis of Presentation

 

The Company’s fiscal year end is December 31. The Company uses the accrual method of accounting. The accompanying unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements. The December 31, 2022 balance sheet has been derived from audited consolidated financial statements.

 

The accompanying unaudited condensed consolidated financial statements for the three months ended March 31, 2023 and 2022 have been prepared in accordance with GAAP for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements.

 

The unaudited financial information included in this report includes all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary to reflect a fair statement of the results for the interim periods. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results of the full fiscal year.

 

The condensed consolidated financial statements included in this report should be read in conjunction with the financial statements and notes thereto included in the Company’s financial statements for the fiscal year ended December 31, 2022.

 

On April 24, 2023, the Company effected a 1-for-50 reverse stock split. As a result of this reverse split, the Company’s issued and outstanding common stock decreased from 40,440,129 shares to 822,303 shares. The impact of this transaction is reflected within all common stock, options, and warrant information retrospectively in these condensed consolidated financial statements.

 

Liquidity, Capital Resources and Going Concern

 

The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has sustained recurring losses and has a deficiency in working capital of approximately $15.0 million at March 31, 2023, which raises substantial doubt about its ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Use of Estimates

 

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. These estimates include, among other items, assessing the collectability of receivables, the realization of deferred taxes, useful lives and recoverability of tangible and intangible assets, assumptions used in the valuation of options, the computation of revenue based on the proportional delivery of services, and accruals for commitments and contingencies. Some of these estimates can be subjective and complex and, consequently, actual results could differ materially from those estimates.

 

Cash Equivalents

 

The Company considers all highly liquid investments purchased with an original maturity of three (3) months or less to be cash equivalents. At March 31, 2023 and December 31, 2022, there were no cash equivalents.

 

 

SMART FOR LIFE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(UNAUDITED)

 

Accounts Receivable and Allowance for Doubtful Accounts

 

The Company’s allowance for doubtful accounts represents the Company’s estimate for uncollectible receivables based on a review of specific accounts and the Company’s historical collection experience. The Company writes off specific accounts based on an ongoing review of collectability, as well as management’s past experience with the customers. Accounts receivable are presented net of an allowance for doubtful accounts of $92,580 and $57,581 at March 31, 2023 and December 31, 2022, respectively.

 

Inventory

 

Inventory consists of raw materials, packaging materials, and finished goods and is valued at the lower of cost (first-in, first-out) (replacement cost or net realizable value). An allowance for inventory obsolescence is provided for slow moving or obsolete inventory to write down historical cost to net realizable value. The Company primarily performs its manufacturing for functional foods and nutraceuticals in the form of bars, cookies, powders, tablets and capsules.

 

The allowance for obsolescence is an estimate established through charges to cost of goods sold. Management’s judgment in determining the adequacy of the allowance is based upon several factors which include, but are not limited to, analysis of slow-moving inventory, analysis of the selling price of inventory, the predetermined shelf life of the product, and management’s judgment with respect to current economic conditions. Given the nature of the inventory, it is reasonably possible the Company’s estimate of the allowance for obsolescence will change in the near term.

 

Property and Equipment

 

Property and equipment are recorded at cost. Expenditures for major betterments and additions are charged to the asset accounts, while replacements, maintenance and repairs which do not improve or extend the lives of the respective assets are charged to expense as incurred. The Company provides for depreciation and amortization over the estimated useful lives of various assets using the straight-line method ranging from 3-15 years.

 

Goodwill

 

The Company allocates goodwill to reporting units based on the reporting unit expected to benefit from the business combination. The Company evaluates its reporting units on an annual basis and, if necessary, reassign goodwill using a relative fair value allocation approach. Goodwill is tested for impairment at the reporting unit level (operating segment or one level below an operating segment) on December 31 and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit.

 

No goodwill impairments were recognized during the three months ended March 31, 2023 and 2022.

 

Intangible Assets

 

Intangible assets consist of customer contracts, developed technology, non-compete agreements, license agreements, and intellectual property acquired in the acquisitions of BSNM, DSO, Nexus, GSP, and Ceautamed. The Company amortizes intangible assets with finite lives on a straight-line basis over their estimated useful lives which ranges from 3 to 15 years.

 

 

SMART FOR LIFE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(UNAUDITED)

 

Long-Lived Assets

 

The Company assesses potential impairments to its long-lived assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. An impairment loss is recognized when the undiscounted cash flows expected to be generated by an asset (or group of assets) is less than its carrying amount. Any required impairment loss is measured as the amount by which the asset’s carrying value exceeds its fair value and is recorded as a reduction in the carrying value of the related asset and a charge to operating results. The Company had no impairment of long-lived assets at March 31, 2023 and December 31, 2022.

 

Lease Right-of-Use Assets and Liabilities

 

The Company records a right-of-use (“ROU”) asset and lease liability on the balance sheet for all leases with terms longer than 12 months. Leases are classified either as finance or operating with the classification affecting the pattern of expense recognition.

 

Related Parties

 

The Company follows Accounting Standards Codification (“ASC”) 850, “Related Party Disclosures,” for the identification of related parties and disclosure of related party transactions (see Note 12).

 

Debt Issuance Costs

 

In accordance with ASC 835-30, Other Presentation Matters, the Company has reported debt issuance cost as a deduction from the carrying amount of debt and amortizes these costs using the effective interest method over the term of the debt as interest expense.

 

Revenue Recognition

 

The Company evaluates and recognizes revenues by:

 

●

identifying the contract(s) with the customer,

 

●

identifying the performance obligations in the contract,

 

●

determining the transaction price,

 

●

allocating the transaction price to performance obligations in the contract; and

 

●

recognizing revenue as each performance obligation is satisfied through the transfer of a promised good or service to a customer (i.e., “transfer of control”).

 

 

SMART FOR LIFE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(UNAUDITED)

 

Products (BSNM, DSO, GSP, and Ceautamed)

 

The Company generates product revenues by manufacturing and packaging of nutraceutical products as a contract manufacturer for customers. The majority of the Company’s revenue is recognized when it satisfies a single performance obligation by transferring control of its products to a customer. Control is generally transferred when the Company’s products are either shipped or delivered based on the terms contained within the underlying contracts or agreements. The Company’s general payment terms are short-term in duration. The Company does not have significant financing components or payment terms. The Company records deferred revenues for prepaid amounts from customers due to no performance obligations being met at such time. The Company did not have any material unsatisfied performance obligations at March 31, 2023 or December 31, 2022.

 

Distribution expenses to transport the Company’s products, where applicable, and warehousing expense after manufacture are accounted for within operating expenses.

 

Advertising /Marketing (Nexus)

 

Nexus generates advertising revenue when sales of listed products are sold by product vendors through its network as a result of the marketing efforts of digital marketers. The products on the network come from several different customers, which pay Nexus a specific amount per sale, the amount of which is dictated by the customer. The revenue is recognized upon the sale of a product by the customer, net of fraudulent traffic or disputed transactions. A portion of the specific amount received by Nexus for that sale is paid out to the digital marketer as a commission, which is recorded in cost of sales.

 

Nexus’ general payment terms are short-term in duration. Nexus does not have significant financing components or payment terms. Nexus did not have any material unsatisfied performance obligations at March 31, 2022 or December 31, 2022.

 

Freight

 

For the three months ended March 31, 2023 and 2022, freight costs amounted to $100,990 and $280,451, respectively, and have been recorded in cost of goods sold in the accompanying condensed consolidated statements of operations.

 

Advertising

 

Advertising costs are expensed as incurred. Advertising costs for the three months ended March 31, 2023 and 2022 were $291,653 and $533,544, respectively.

 

Paycheck Protection Program

 

The Company records Paycheck Protection Program (“PPP”) loan proceeds in accordance with ASC 470, Debt. Debt is extinguished when either the debtor pays the creditor or the debtor is legally released from being the primary obligor, either judicially or by the creditor.

 

Stock-based Compensation

 

The Company recognizes expense for stock options and warrants granted over the vesting period based on the fair value of the award at the grant date and valued using a Black-Scholes option pricing model to determine the fair market value of the stock options. Forfeitures are reduced from warrants outstanding and the Company calculates the amount of tax benefit available by tracking each stock option award on an employee-by-employee basis and on a grant-by-grant basis. The Company then compares the recorded expense to the tax deduction received for each stock option grant. The Company’s policy is to recognize forfeitures as they occur.

 

 

SMART FOR LIFE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(UNAUDITED)

 

Income Taxes

 

The Company accounts for income taxes under the provisions of ASC 740, Income Taxes. The Company records a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. At March 31, 2023 and December 31, 2022, the Company had no liabilities for uncertain tax positions. The Company continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings. The Company’s tax years subject to examination by tax authorities generally remain open for three (3) years from the date of filing.

 

The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax assets are expected to be realized or settled. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized. Due to the continued losses, the Company has recorded a full valuation allowance at the end of March 31, 2023 and December 31, 2022.

 

Recent Accounting Standards Not Yet Adopted

 

On August 5, 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-06, ““Debt – Debt With Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40),” which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in GAAP. This ASU is effective for fiscal years beginning after December 31, 2023. The Company is evaluating the impact the adoption will have on the financial statements.

 

Note 3 — Inventory

 

Inventory consisted of the following:

 

		March 31, 2023				December 31, 2022
Raw materials		$	572,185			$	644,202
Packaging materials			960,921				946,884
Finished goods			562,106				1,074,415
			2,095,212				2,665,501
		$	2,095,212			$	2,665,501

 

 

SMART FOR LIFE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(UNAUDITED)

 

Note 4 — Property and Equipment

 

Property and equipment consisted of the following:

 

		Estimated Useful Lives (in Years)		March 31, 2023				December 31, 2022
Furniture and fixtures		7		$	9,139			$	9,139
Equipment – Manufacturing		5			1,342,702				1,342,702
Building & Equipment		5			3,840				3,840
Leasehold improvements		3.5			90,099				90,099
					1,445,780				1,445,780
Less: accumulated depreciation and amortization					(1,044,553	)			(963,561	)
Property and equipment, net				$	401,227			$	482,219

 

Depreciation and amortization expense for the three months ended March 31, 2023 and 2022 totaled $80,992 and $67,547, respectively, which is included in depreciation and amortization expense.

 

Note 5 — Intangible Assets

 

Intangible assets consisted of the following:

 

		Estimated Useful Lives (in Years)		March 31, 2023				December 31, 2022
Customer contracts		10		$	11,848,839			$	11,848,839
Developed technology		15			1,570,000				1,570,000
Non-compete agreements		3			1,595,530				1,595,530
Patents		5			230,000				230,000
Tradename		15			2,010,000				2,010,000
Intellectual property		10			5,582,436				5,582,436
Licenses agreements		5			584,220				584,220
Total intangible assets					23,421,025				23,421,025
Less: amortization					(3,094,985	)			(2,484,767	)
Intangibles, net				$	20,326,040			$	20,936,258

 

Amortization for the three months ended March 31, 2023 and 2022 was $610,218 and $355,463, respectively, which is included in depreciation and amortization expense.

 

The future amortization is as follows:

 

Years Ending December 31:
2023 (remainder of year)		$	1,830,654
2024			2,440,871
2025			2,331,770
2026			2,124,956
2027			2,006,901
Thereafter			9,590,888
Total		$	20,326,040

 

 

SMART FOR LIFE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(UNAUDITED)

 

Note 6 — Leases

 

Leases Involving Real Estate

Leases of distribution and manufacturing facilities, customer support centers and the Company’s corporate headquarters have lease terms that generally range from 5 to 7 years.

Rental payments on these leases typically provide for fixed minimum payments that increase over the lease term at predetermined amounts. Certain leases of real estate provide for rental increases based on the CPI, which are included in the Company’s measurement of lease payments based on the rate or index in effect at lease commencement, and are therefore included in the measurement of the lease liabilities.

 

Leases Involving Equipment

Equipment leases have lease terms that generally range from less than 4 years to 5 years. Rental payments on these leases typically provide for fixed minimum payments that increase over the lease term at predetermined amounts, are included in the measurement of lease payments, and are included in the measurement of lease liabilities. Certain of the leases involving equipment have purchase options. When those options are reasonably certain of being exercised, the Company reflects such purchase options when measuring the lease term and lease payments for those leases.

 

Financial Information

The following provides information about the Company’s right of use assets and lease liabilities for its operating and finance leases as of March 31, 2023 and December 31, 2022:

 

		Balance Sheet classification		March 31, 2023				December 31, 2022
Right of use assets Operating leases		Operating leases right-of-use asset		$	2,590,839			$	2,672,866
Lease liabilities
Current
Operating leases		Operating lease liabilities, current portion			317,606				303,819
Noncurrent
Operating leases		Operating lease liabilities, non-current portion			2,337,617				2,423,446
Total lease liabilities				$	2,655,223			$	2,727,265

 

SMART FOR LIFE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(UNAUDITED)

 

The components of the Company’s lease cost for the three months ended March 31, 2023 and 2022 are as follows:

 

		Income Statement Classification		March 31, 2023				March 31, 2022
Rent expense		General and administration		$	160,216			$	161,722

 

Supplemental cash flow information related to Company’s leases for the three months ended March 31, 2023: 

 

			Operating leases
Cash paid for amounts included in the measurement of lease liabilities		$	150,231

 

Weighted average remaining lease term and weighted average discount rate for the Company’s leases as of March 31, 2023: 

 

		Operating leases
Weighted average remaining term (in years)			5.67
Weighted average discount rate			12.00	%

 

Annual maturity analysis of the Company’s lease liabilities as of March 31, 2023:

 

		Operating leases
2023		$	461,685
2024			633,038
2025			651,829
2026			671,213
2027			658,622
Thereafter			636,775
Total payments			3,713,162
Less: interest			(1,057,939	)
Present value of lease liability			2,655,223
Less: Current portion of lease liabilities			(317,606	)
Noncurrent portion of lease liabilities		$	2,337,617

 

 

SMART FOR LIFE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(UNAUDITED)

 

Note 7 — Debt

 

Original Issue Discount Subordinated Debentures

 

In June 2022, the Company commenced offerings of original issue discount subordinated debentures. As of March 31, 2023, the Company has completed multiple closings and issued debentures in the aggregate principal amount of $4,764,099, of which $847,060 was issued with issuances costs of $127,060 for the three months ended March 31, 2023. The debentures contain an original issue discount of 15%, or an aggregate original issue discount of $713,830. As a result, the total purchase price was $4,050,270. The debentures bear interest at a rate of 17.5% per annum and are due from January through November 2024. The outstanding principal amount and all accrued interest is due and payable on the earlier of (i) the completion of the Company’s next equity financing in which it receives gross proceeds in excess of $20 million, (ii) twenty-four months after the date of issuance or (iii) within 30 days after election of repayment from the holder so long as the election is after the 6-month anniversary of the debenture. The Company may voluntarily prepay the debentures in whole or in part without premium or penalty. The debentures contain customary events of default for a loan of this type. The debentures are unsecured and are subordinated in right of payment to the prior payment in full of all senior indebtedness and are pari passu in right of payment to any other unsecured indebtedness incurred by the Company in favor of any third party. As of March 31, 2023, the outstanding principal balance of the debentures was $4,758,830, the unamortized debt issuance cost was $367,399 and accrued interest was $483,768.

 

Original Issue Discount Secured Subordinated Note

 

On July 29, 2022, the Company entered into a securities purchase agreement with an accredited investor, pursuant to which it sold an original issue discount secured subordinated note in the principal amount of $2,272,727 to such investor. The note contains an original issue discount of 12%, or $272,727. As a result, the total purchase price was $2,000,000, the proceeds of which were used to fund the acquisition of Ceautamed. The note shall bear interest at the rate of 16% per annum and matures on July 29, 2027. The outstanding principal and all accrued interest shall be amortized on a 60-month straight-line basis. The Company may prepay the principal and all accrued and unpaid interest on the note without penalty, in whole or in part; provided however, in no event before January 15, 2023, unless with the explicit prior written approval of the holder. The note contains customary events of default for a loan of this type. The note is guaranteed by BSNM, DSO, Nexus, GSP and Ceautamed and is secured by a security interest in all of the assets of the Company and such guarantors; provided that such security interest is subordinate to the rights of the lenders under any senior indebtedness (as defined in the note). As of March 31, 2023 the outstanding principal balance of the note was $2,212,177, the unamortized debt issuance cost was $213,880 and accrued interest was $89,714.

 

Acquisition Notes

 

On July 1, 2021, the Company issued a 6% secured subordinated promissory note in the principal amount of $3,000,000 to a related party, Sasson E. Moulavi (“Dr. Moulavi”), in connection with the acquisition of DSO. This note accrues interest at 6% per annum and the outstanding principal and interest will be amortized on a straight-line basis and are payable quarterly in accordance with the amortization schedule, with all amounts due and payable on July 1, 2024. On November 29, 2022, the Company entered into a letter agreement with Sasson E. Moulavi to amend the terms of the note. Pursuant to the letter agreement, the parties agreed to amend and restate the note to amend the amortization schedule, with the first payment deferred until February 15, 2023 and all amounts due and payable on August 15, 2024. In exchange for the agreement of Dr. Moulavi to enter into the letter agreement, the Company agreed to (i) issue to Dr. Moulavi 100,000 shares of common stock under the Company’s 2022 Equity Incentive Plan and (ii) pay to Dr. Moulavi a fee of $50,000 in cash, which shall be paid upon completion of the Company’s anticipated debt financing and is included in debt balance. The Company may prepay all or any portion of this note any time prior to maturity without premium or penalty. This note contains customary covenants and events of default for a loan of this type, including if a default occurs under any senior secured indebtedness to banks and other financial institutions or private equity funds, and is secured by a security interest in all of the assets of DSO; provided that such security interest is subordinate to the rights of the lenders under any such senior secured indebtedness. As of March 31, 2023, the outstanding principal balance of this note was $3,050,000 and accrued interest was $324,317.

 

 

SMART FOR LIFE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(UNAUDITED)

 

On November 8, 2021, the Company issued a 5% secured subordinated promissory note in the principal amount of $1,900,000 to related parties, Justin Francisco and Steven Rubert, in connection with the acquisition of Nexus. This note accrues interest at 5% per annum and the outstanding principal and interest will be amortized on a straight-line basis and are payable quarterly in accordance with the amortization schedule attached to the note, with all amounts due and payable on November 8, 2024. The Company may prepay all or any portion of this note any time prior to maturity without premium or penalty. The note contains customary covenants and events of default for a loan of this type, including if a default occurs under any senior secured indebtedness to banks and other financial institutions or private equity funds, and is secured by a security interest in all of the Company’s assets; provided that such security interest is subordinate to the rights of the lenders under any such senior secured indebtedness. As of March 31, 2023, the outstanding principal balance of this note was $1,900,000 and accrued interest was $134,056.

 

On July 29, 2022, the Company issued secured subordinated convertible promissory notes in the aggregate principal amount of $2,150,000 in connection with the acquisition of Ceautamed, which are partially with a related party. The notes shall bear interest at the rate of 5% per annum with all principal and accrued interest being due and payable in one lump sum on July 29, 2025; provided that upon an event of default (as defined in the notes), such interest rate shall increase to 10%. The notes are convertible at the option of the holder into common stock at a conversion price of $6.25; provided that the holder may not elect to convert a portion of the outstanding principal in an amount less than the lesser of $200,000 or the remaining outstanding principal. The notes contain customary covenants and events of default for loans of this type, including upon any default under the senior indebtedness (as defined in the notes). The notes are guaranteed by Ceautamed and are secured by a security interest in all of the assets of such guarantors; provided that such security interest is subordinate to the rights of the lenders under any such senior indebtedness. As of March 31, 2023, the outstanding principal balance of these notes was $2,150,000 and accrued interest was $73,160.

 

On July 29, 2022, the Company issued secured subordinated promissory notes in the aggregate principal amount of $2,150,000 in connection with the acquisition of Ceautamed, which are partially with a related party. The notes shall bear interest at the rate of 5% per annum and mature on July 29, 2025; provided that upon an event of default (as defined in the notes), such interest rate shall increase to 10%. The outstanding principal and all accrued interest shall be amortized on a five-year straight-line basis and payable quarterly in accordance with the amortization schedule to the notes. The Company may redeem all or any portion of the notes at any time without premium or penalty. The notes contain customary covenants and events of default for loans of this type, including upon any default under the senior indebtedness (as defined in the notes). The notes are guaranteed by Ceautamed and are secured by a security interest in all of the assets of such guarantors; provided that such security interest is subordinate to the rights of the lenders under any such senior indebtedness. As of March 31, 2023, the outstanding principal balance of these notes was $2,204,993, unamortized debt issuance cost was $54,993 and accrued interest was $75,031.

 

On July 29, 2022, the Company issued secured subordinated promissory notes in the aggregate principal amount of $1,300,000 in connection with the acquisition of Ceautamed, which are partially with a related party. The notes bore interest at the rate of 5% per annum with all principal and accrued interest being due and payable in one lump sum ninety (90) days from the date of the note; provided that upon an event of default (as defined in the notes), such interest rate shall increase to 10%. On November 28, 2022, the Company entered into letter agreements with the holders of most of the notes to amend the terms of these notes. Pursuant to letter agreements, the parties agreed to extend the maturity date to June 1, 2023 and agreed to a seven month payment schedule, with the first payment due December 1, 2022. The parties also agreed to increase the default interest rate from 10% to 15%. The Company also agreed that if an event of default (as defined in the notes) has occurred and is continuing, then the Company shall not create any senior indebtedness (as defined in the notes) without the consent of the holders of a majority of the principal amount of the notes. In exchange for the agreement of the holders to enter into the letter agreements, the Company agreed to pay certain amendment fees as more particularly described in the letter agreements. The Company is in the process of negotiating a similar extension of one remaining note in the principal amount of $100,000. The Company may redeem all or any portion of the notes at any time without premium or penalty. The notes contain customary covenants and events of default for loans of this type, including upon any default under the senior indebtedness (as defined in the notes). The notes are guaranteed by Ceautamed and are secured by a security interest in all of the assets of such guarantors; provided that such security interest is subordinate to the rights of the lenders under any such senior indebtedness. As of March 31, 2023, the outstanding principal balance of these notes was $1,148,000, unamortized debt issuance cost was $108,000 and accrued interest was $92,011.

 

 

SMART FOR LIFE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(UNAUDITED)

 

Other Promissory Notes and Cash Advances

 

Promissory Notes

 

On July 1, 2021, the Company entered into a loan agreement with Diamond Creek Capital, LLC for a term loan in the principal amount of up to $3,000,000. The loan bears interest at a rate of 15.0% per annum, provided that upon an event of default, such rate shall increase by 5%. The loan was due and payable on the earlier of July 1, 2022 or upon completion of the IPO. The Company repaid $1,325,000 of the principal balance and $27,604 of the interest from the proceeds of the IPO. In connection with such repayment, the lender agreed that the remaining loan is due and payable on July 1, 2023. The loan is secured by all of the Company’s assets and contains customary events of default. As of March 31, 2023, the outstanding principal balance of this note was $1,075,000 and accrued interest was $69,475.

 

In 2018, the Company entered into an amended loan agreement and convertible promissory note for $200,000 with a third party. On March 31, 2023, the outstanding amount was $200,000 and accrued interest was $155,484.

 

In October 12, 2022, the Company issued promissory notes in the principal amount of $258,000 to third parties. These promissory notes bear interest of 15% to 20% and payable on December 2022 and January 2023. As of March 31, 2023, the outstanding principal balance was $258,000 and accrued interest was $9,371.

 

On November 2, 2022, the Company issued a promissory note to a board member in the principal amount of $50,000. This note bears interest at a rate of 12% and is due on demand. At March 31, 2023, the outstanding amount was $20,000 and accrued interest was $605.

 

On December 6, 2022, the Company issued a promissory note to a board member in the principal amount of $30,000. This note bears interest at a rate of 12% and is due on demand. At March 31, 2023, the outstanding amount was $30,000 and accrued interest was $1,150.

 

On December 21, 2022, the Company issued a promissory note to a board member in the principal amount of $100,000. This note bears interest at a rate of 12% and is due on demand. At March 31, 2023, the outstanding amount was $100,000 and accrued interest was $3,333.

 

On February 8, 2023, the Company issued a promissory note to a board member in the principal amount of $50,000. This note bears interest at a rate of 12% and is due on demand. At March 31, 2023, the outstanding amount was $50,000 and accrued interest was $850.

 

On February 14, 2023, the Company issued a promissory note to a third party in the principal amount of $50,000. This note bears interest at a rate of 12% and is due on demand. At March 31, 2023, the outstanding amount was $50,000 and accrued interest was $740. 

 

On February 16, 2023, the Company issued a promissory note to a third party in the principal amount of $50,000. This note bears interest at a rate of 12% and is due on August 26, 2023. At March 31, 2023, the outstanding amount was $50,000 and accrued interest was $658.

 

On March 7, 2023, the Company issued a promissory note to a board member in the principal amount of $137,000. This note bears interest at a rate of 12% and is due on demand. At March 31, 2023, the outstanding amount was $137,000 and accrued interest was $977.

 

Cash Advances

 

In June 2022, the Company entered into a cash advance agreement for $341,150 with a required repayment amount of $490,000, which requires weekly payments of approximately $19,738. At March 31, 2023, the outstanding amount was $22,124.

 

In July 2022, the Company entered into a cash advance agreement for $650,000 with a required repayment amount of $897,750, which requires weekly payments of approximately $40,806. At March 31, 2023, the outstanding amount was $474,690.

 

In August 2022, the Company entered into a cash advance agreement for $100,000 with a required repayment amount of $146,260, which requires weekly payments of approximately $6,200. At March 31, 2023, the outstanding amount was $4,360.

 

In September 2022, the Company entered into a cash advance agreement for $243,750 with a required repayment amount of $372,500, which requires weekly payments of approximately $15,000. At March 31, 2023, the outstanding amount was $232,500.

 

 

SMART FOR LIFE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(UNAUDITED)

 

In November 2022, the Company entered into cash advance agreements for $592,236 with a required repayment amount of $994,460, which requires weekly payments of approximately $52,422. At March 31, 2023, the outstanding amount was $497,296 and unamortized debt issuance cost of $138,365.

 

In December 2022, the Company entered into cash advance agreements for $293,000 with a required repayment amount of $439,207, which requires weekly payments of approximately $39,905. At March 31, 2023, the outstanding amount was $81,271 and unamortized debt issuance cost of $14,257.

 

In January 2023, the Company entered into cash advance agreements for $321,000 with a required repayment amount of $593,604, which requires weekly payments of approximately $39,980. At March 31, 2023, the outstanding amount was $542,934 and unamortized debt issuance cost of $8,705.

 

Equipment Financing Loan

 

In May 2022, the Company entered into an equipment financing loan for $146,765 used for the purchase of equipment within BSNM’s operations. The loan bears interest at 10.18% and matures on April 1, 2027. At March 31, 2023, the outstanding amount was $127,152.

 

In August 2022, the Company entered into an equipment financing loan for $35,050 used for the purchase of equipment within BSNM’s operations. The loan bears interest at 10.18% and matures on August 1, 2027. At March 31, 2023, the outstanding amount was $32,167.

 

In July 2022, the Company entered into an equipment financing loan for $8,463 used for the purchase of equipment within Ceautamed’s operations. At March 31, 2023, the outstanding amount was $6,412.

 

Revolving Lines of Credit

 

In 2021, DSO entered into two revolving lines of credit with a bank, which permit borrowings up to $958,000, and bear interest at 9.49%.As of March 31, 2023, the outstanding principal balance of these lines of credit was $412,184. 

 

In August 2022, Ceautamed entered into a revolving line of credit with a bank, which permit borrowings up to $50,000, and bear interest at 45.09%. As of March 31, 2023, the outstanding principal balance of these lines of credit was $48,556. 

 

In September 2022, DSO entered into a revolving line of credit with a bank, which permit borrowings up to $70,000, and bear interest at 9.49%. As of March 31, 2023, the outstanding principal balance of this line of credit was $38,671. 

 

EIDL Loan

 

In June 2020, pursuant to the economic injury disaster loan (“EIDL”) program under the under the provisions of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), the Company entered into a promissory note with the U.S. Small Business Administration (the “SBA”) with a principal amount of $300,000. This loan matures in 30 years and bears interest at a rate of 3.75%. The loan is secured by all of the Company’s assets. As of March 31, 2023, the outstanding principal balance of this loan was $300,000 and accrued interest was $31,063.

 

PPP Loans

 

In February 2021, the Company received an additional $261,164 in PPP loans under the CARES Act. This loan bears interest at a rate of 1% per annum and matures in April 2025. As of March 31, 2023, the outstanding balance of this loan was $197,457 and accrued interest was $8,923.

 

 

SMART FOR LIFE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(UNAUDITED)

 

Total Debt

 

Debt is comprised of the following components as of March 31, 2023:

 

Original issue discount subordinated debentures		$	4,758,830
Original issue discount secured subordinated note			2,212,177
Acquisition notes			10,452,993
Promissory notes and cash advances			3,825,175
Revolving lines of credit			499,411
Equipment financing loan			165,731
EIDL loan			300,000
PPP loans			197,457
			22,411,774
Debt issuance costs			(742,608	)
Debt, net			21,669,166
Debt, current			8,378,622
Debt issuance costs, current			(508,437	)
Current portion of debt, net			7,870,185
Debt, non-current			14,033,152
Debt issuance costs, non-current			(234,171	)
Non-current portion of debt, net		$	13,798,981

 

The future contractual maturities of the debt are as follows:

 

For the Year Ended December 31:
2023 (remainder of year)		$	7,869,424
2024			8,461,395
2025			4,148,016
2026			464,375
2027			513,676
Thereafter			212,280
Total		$	21,669,166

 

Note 8 — Concentrations of Credit Risks

 

Credit Risks

 

Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and accounts receivable. The Company maintains bank accounts with several financial institutions. Concentrations of credit risk with respect to accounts receivable are limited to the dispersion of customers across different industries and geographic regions.

 

Cash

 

The Company places its cash with high credit quality financial institutions. At March 31, 2023 and December 31, 2022, the Company had no cash balances in excess of the Federal Deposit Insurance Corporation coverage of $250,000 per institution. The Company has not experienced any losses in such accounts.

 

Major Customers

 

For the three months ended March 31, 2023, the Company had two significant customers representing an aggregate of 46% of revenues and one that makes up 26% of the accounts receivable balance. For the three months ended March 31, 2022, the Company had two significant customers representing an aggregate of 45% of revenues and three that make up 78% of the accounts receivable balance.  The Company’s officers are closely monitoring the relationships with all customers.

 

Major Vendors

 

For the three months ended March 31, 2023, the Company had one major supplier representing an aggregate of 22% of purchases. For the three months ended March 31, 2022, the Company had two major suppliers representing an aggregate of 21% of purchases. The Company’s officers are closely monitoring the relationships with all significant suppliers.

 

 

SMART FOR LIFE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(UNAUDITED)

 

Note 9 — Income Taxes

 

The Company has evaluated the positive and negative evidence in assessing the realizability of its deferred tax assets. This assessment included the evaluation of scheduled reversals of deferred tax liabilities, estimates of projected future taxable income and tax planning strategies to determine which deferred tax assets are more likely than not to be realized in the future.

 

The Company records a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. Interest and penalties related to income tax matters, if any, would be recognized as a component of income tax expense. At March 31, 2023 and December 2022, the Company had no liabilities for uncertain tax positions. The Company continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings. Currently, the tax years subsequent to 2018 are open and subject to examination by the taxing authorities.

 

At March 31, 2023, the Company had net operating loss carry forwards for federal income tax purposes of approximately $15.5 million, which will be available to offset future taxable income.

 

Note 10 — Stockholders’ Equity

 

Preferred Stock

 

On June 29, 2021, the Company filed a certificate of designation with the Delaware Secretary of State to establish its series A convertible preferred stock. The Company designated a total of 8,000 shares of its preferred stock as series A convertible preferred stock. The series A convertible preferred stock has the following voting powers, designations, preferences and relative rights, qualifications, limitations or restrictions:

 

Dividend Rights. Prior to February 14, 2022 (the IPO Date), holders of series A convertible preferred stock were entitled to receive cumulative dividends at a rate of 7.5% of the stated value per share ($1,000, subject to adjustment) per annum, which increased to 15% per annum after November 23, 2021 and 24% per annum after December 31, 2021. Holders of series A convertible preferred stock are no longer entitled to dividends. The dividend accrual was $600,750 as of March 31, 2023.

 

Liquidation Rights. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, or upon a change of control, the holders of series A convertible preferred stock shall be entitled to receive out of the assets of the Company the same amount that a holder of common stock would receive if the series A convertible preferred stock were fully converted (disregarding for such purposes any conversion limitations) to common stock which amounts shall be paid pari passu with all holders of common stock.

 

Voting Rights. The series A convertible preferred stock has no voting rights except as set forth below. As long as any shares of series A convertible preferred stock are outstanding, the Company shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the series A convertible preferred stock, (a) alter or change adversely the powers, preferences or rights given to the series A convertible preferred stock or alter or amend the certificate of designation, (b) authorize or create any class of stock ranking as to dividends, redemption or distribution of assets upon a liquidation senior to, or otherwise pari passu with, the series A convertible preferred stock, (c) amend the certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of series A convertible preferred stock, or (d) enter into any agreement with respect to any of the foregoing.

 

Conversion Rights. Each share of series A convertible preferred stock is convertible, at any time and from time to time from at the option of the holder thereof, into that number of shares of common stock determined by dividing the stated value of such share of series A convertible preferred stock (plus any accrued but unpaid dividends thereon) by the conversion price. The conversion price is initially equal to $0.6667 (subject to adjustments). Notwithstanding the foregoing, the Company shall not effect any conversion, and a holder shall not have the right to convert, any portion of the series A convertible preferred stock to the extent that, after giving effect to the conversion, such holder (together with such holder’s affiliates) would beneficially own in excess of 4.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares issuable upon the conversion. This limitation may be waived (up to a maximum of 9.99%) by the holder and in its sole discretion, upon not less than sixty-one (61) days’ prior notice to the Company.

 

 

SMART FOR LIFE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(UNAUDITED)

 

Common Stock

 

On February 16, 2022, the Company entered into an underwriting agreement with Dawson James Securities, Inc., as representative of the several underwriters named on Schedule I thereto, relating to its IPO of units, each unit consisting of one share of common stock, a series A warrant to purchase one share of common stock and a series B warrant to purchase one share of common stock. Pursuant to the underwriting agreement, the Company agreed to sell 28,800 units to the underwriters, at a purchase price per unit of $455.00 (the offering price to the public of $500.00 per unit minus the underwriters’ discount), and also agreed to grant to the underwriters a 45-day option to purchase up to 4,320 additional shares of common stock, up to 4,320 additional series A warrants, and/or up to 4,320 additional series B warrants, in any combination thereof, at a purchase price to the public of $499.00 per share and $0.50 per warrant, less underwriting discounts and commissions, solely to cover over-allotments, if any.

 

On February 18, 2022, the closing of the IPO was completed. At the closing, the underwriters partially exercised the option and purchased 4,128 series A warrants and 4,128 series B warrants. Therefore, the Company sold 28,800 shares of common stock, 32,928 series A warrants and 32,928 series B warrants for total gross proceeds of $14,404,128. After deducting the underwriting commission and expenses, the Company received net proceeds of $12,738,288.

 

On February 18, 2022, the Company issued 7,730 shares of common stock upon the conversion of the 5% secured subordinated convertible promissory note in the principal amount of $1,900,000 along with interest of $32,500 issued to Justin Francisco and Steven Rubert in connection with the acquisition of Nexus.

 

On February 18, 2022, the Company issued 12,464 shares of common stock upon the conversion of the 6% secured subordinated convertible promissory note in the principal amount of $3,000,000 along with interest of $116,000 issued to Sasson E. Moulavi in connection with the acquisition of DSO.

 

On February 18, 2022, the Company issued 4,597 shares of common stock upon the conversion of the convertible promissory note in the principal amount of $500,000 along with interest of $74,583 issued to East West Capital LLC.

 

On February 18, 2022, the Company issued 850 additional shares of common stock to the stockholders of GSP and 295 additional shares of common stock to certain vendors of GSP in accordance with the terms of the contribution and exchange agreement described above. Based on the IPO share allocation of the unit, it was determined that the Company would issue the additional 850 shares.

 

On February 18, 2022, the Company issued an aggregate of 43,370 shares of common stock to various lenders pursuant to future equity agreements which required the Company to issue shares of common stock upon closing of the IPO, which resulted in an interest expense of $10,844,960.

 

In February through March 2022, the Company issued 23,652 shares of common stock upon the conversion of the convertible promissory note in the principal amount of $2,250,000 along with interest of $292,500 issued to several debt holders.

 

On March 10, 2022, the Company granted restricted stock awards for an aggregate of 17,540 shares of common stock to certain directors, officers, and consultants. A total of 13,540 of these shares vested in full on the date of grant. The remaining 4,000 shares, which were granted to independent directors, vest monthly over a one-year period which were recorded as a prepaid of $46,900 at December 31, 2022. A total of 10,940 of these shares were granted under the 2020 Stock Incentive Plan described below. The remaining 6,600 were granted under the 2022 Equity Incentive Plan described below. The shares, valued at $822,626, were based on the closing trading price per share of $46.90 on the date of the grant.

 

During the three months ended March 31, 2023, the Company issued 61,495 shares of common stock upon exercise of warrants.

 

 

SMART FOR LIFE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(UNAUDITED)

 

Stock Options and Warrants

 

In September 2020, the Company adopted its 2020 Incentive Plan (the “2020 Plan”) under which the Company is authorized to issue awards for up to 40,000 shares of common stock to directors, officers, employees, and consultants who provide services to the Company. Awards that may be granted include incentive stock options, non-qualified stock options and awards of restricted stock.

 

At March 31, 2023 and December 2022, there were 15,000 shares of common stock available for issuance under the 2020 Plan. The Company did not issue any other stock options under the 2020 Plan during the three months ended March 31, 2023.

 

In January 2022, the Company adopted its 2022 Equity Inventive Plan (the “2022 Plan”) under which the Company is authorized to issue awards for up to 1,400,000 shares of common stock to directors, officers, employees, and consultants who provide services to the Company. Awards that may be granted include incentive stock options, non-qualified stock options, stock appreciation rights, restricted awards, performance share awards and performance compensation awards. At March 31, 2023, there were 1,375,480 shares of common stock available for issuance under the 2022 Plan.

 

On August 12, 2022, the Company issued stock options to employees under the 2022 Plan for an aggregate of 26,560 shares of common stock. The stock options have an exercise price of $31.50 per share, will vest quarterly over a three-year period and expire ten (10) years after the date of issuance; provided that an option granted to Alfonso J. Cervantes, Jr., the Company’s Executive Chairman, for the purchase of 6,000 shares of common stock has an exercise price of $34.65 per share and expires five (5) years after the date of issuance. The Company did not issue any other stock options under the 2022 Plan during the three months ended March 31, 2023.

 

The Company recognized $52,473 and $0 of compensation expense related to the vesting of options during the three months ended March 31, 2023 and 2022, respectively.

 

The series A warrants sold in the IPO are exercisable until the fifth anniversary of the issuance date at an exercise price equal to $350.00 per share and may be exercised on a cashless basis if the issuance of common stock upon exercise of the warrants is not covered by an effective registration statement. The exercise price and number of shares of common stock issuable upon exercise of the series A warrants may be adjusted in certain circumstances, including in the event of a stock dividend, extraordinary dividend on or recapitalization, reorganization, merger, or consolidation.

 

The series B warrants sold in the IPO are exercisable until the fifth anniversary of the issuance date at an exercise price equal to $500.00 per share and may be exercised on a cashless basis, whereby the holder will receive one share of common stock for each series B warrant exercised. As of December 31, 2022, 28,785 of the series B warrants were exercised on a cashless basis and the Company issued 28,785 shares of common stock upon such exercise.

 

In January 2023, warrant holders exercised an aggregate of 61,495 shares on a cashless basis.

 

The following is a summary of options and warrants granted, exercised, forfeited and outstanding during the three months ended March 31, 2023:

 

		2023-Stock Options								2023-Warrants
		Number of Options				Weighted Average Exercise Price				Number of Warrants				Weighted Average Exercise Price
Outstanding at January 1, 2023			51,560			$	16.77				4,561,724			$	6.62
Granted			—				—				—				—
Exercised			—				—				61,495				0.01
Forfeited			120				—				10				0.01
Outstanding at March 31			51,440			$	16.77				4,500,219			$	6.62
Exercisable at March 31			26,476								4,500,219

 

 

SMART FOR LIFE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(UNAUDITED)

 

		2022-Stock Options								2022-Warrants
		Number of Options				Weighted Average Exercise Price				Number of Warrants				Weighted Average Exercise Price
Outstanding at beginning of year			29,000			$	0.50				296,040			$	5.79
Granted			—				—				67,656				7.00
Exercised			—				—				28,755				—
Forfeited			—				—				5,520				—
Outstanding at March 31,			29,000			$	0.50				329,421			$	6.64
Exercisable at March 31,			29,000								87,033

 

Valuation Assumptions for Stock Options and Warrants

 

The fair value of each option and warrant was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:

 

Risk-free interest rate			2.90	%
Expected volatility			80	%
Expected life (years)			5
Dividend yield			0	%

 

The expected life represents the weighted average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company’s historical exercise patterns. The risk-free rate is based on the U.S. Treasury yield constant maturity in effect at the time of grant for periods corresponding with the expected life of the option.

 

Net Loss Per Share

 

Basic and diluted net loss per share of common stock for the three months ended March 31, 2023, and 2022 was determined by dividing net loss by the weighted average shares of common stock outstanding during the period. The Company’s potentially dilutive shares, consisting of 4,500,219 warrants and 51,440 stock options, have not been included in the computation of dilutive net loss per share for the periods as the result would be antidilutive.

 

Note 11 — Commitments and Contingencies

 

Legal Matters

 

From time to time, the Company may become subject to threatened and/or asserted claims arising in the ordinary course of business. Management is not aware of any matters, either individually or in the aggregate, that are reasonably likely to have a material adverse effect on the Company’s financial condition, results of operations or liquidity.

 

Note 12 — Related Party Transactions

 

The Company entered into debt with related parties which are reflected in Note 7.

 

The Company is party to a management services agreement with Trilogy Capital Group, LLC (“Trilogy”), a company controlled by the Company’s Executive Chairman. For the three months ended March 31, 2023 and 2022, the Company paid Trilogy $27,547 and $0, respectively, for services rendered under a consulting agreement which are reflected in the statements of operations as consulting fees – related parties.

 

In January 2023, the Company entered into a short-term advance for $12,700 with its Chairman to be repaid on demand.

 

 

SMART FOR LIFE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(UNAUDITED)

 

Note 13 — Subsequent Events

 

In accordance with ASC 855-10, the Company has reviewed its operations subsequent to March 31, 2023 to the date these condensed consolidated financial statements were issued, and has determined that, except as set forth below, it does not have any material subsequent events to disclose in these financial statements.

 

Conversion to Nevada and Increase in Authorized Stock

 

On April 10, 2023, the Company converted from a Delaware corporation to a Nevada corporation by filing: (i) a certificate of conversion with the Secretary of State of the State of Delaware; (ii) articles of conversion with the Secretary of State of the State of Nevada; and (iii) articles of incorporation with the Secretary of State of the State of Nevada. The Company also filed a certificate of designation for the Company’s series A convertible preferred stock with the Secretary of State of the State of Nevada and adopted new bylaws. At the time of the conversion:

 

●

the Company’s domicile changed from the State of Delaware to the State of Nevada;

 

●

the affairs of the Company ceased to be governed by the General Corporation Law of the State of Delaware and the Company’s prior certificate of incorporation and bylaws, and instead became governed by the Nevada Revised Statutes and the articles of incorporation and new bylaws;

 

●

the Company continued to be the same entity and continues with all of the same rights, privileges and powers;

 

●

the Company continued to have the same name, possesses all of the same properties, continued with all of debts, liabilities and obligations, and continued with the same officers and directors as immediately prior to the conversion;

 

●

the number of shares of common stock that the Company is authorized to issue increased from 100 million shares to 500 million shares;

 

●

each outstanding share of the common stock, series A convertible preferred stock, warrants to purchase shares of common stock and other convertible securities of the Company previously incorporated in Delaware (“SMFL Delaware”) automatically converted into one share of common stock, one share of series A convertible preferred stock and an equivalent number of convertible securities of the Company incorporated in Nevada (“SMFL Nevada”), with the same price per share, upon the same terms and subject to the same conditions as before the conversion, and certificates issued for shares of SMFL Delaware’s common stock and series A convertible preferred stock prior to the conversion automatically came to represent shares of SMFL Nevada’s common stock and series A convertible preferred stock upon completion of the conversion; and

 

●

the Company’s employee benefit and incentive plans continued, and each option, equity award or other right of SMFL Delaware issued under such plans automatically converted into an option, equity award or right to purchase or receive the same number of shares of common stock of SMFL Nevada, at the same price per share, upon the same terms and subject to the same conditions as before the conversion.

 

Reverse Stock Split

 

On April 24, 2023, the Company effected a 1-for-50 reverse stock split. As a result of this reverse split, the Company’s issued and outstanding common stock decreased from 40,440,129 shares to 822,303 shares. The impact of this transaction is reflected within all common stock, options, and warrant information retrospectively in the condensed, consolidated financial statements.

 

 

SMART FOR LIFE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(UNAUDITED)

 

Registered Direct Offering and Related Private Placement

 

On May 2, 2023, the Company entered into a securities purchase agreement with an institutional investor, pursuant to which the Company agreed to issue and sell, in a registered direct offering, 94,600 shares of common stock and a pre-funded warrant to purchase up to 186,001 shares of common stock at an exercise price of $0.0001, at an offering price per share and pre-funded warrant of $3.205 and $3.2049, respectively. In addition, under the securities purchase agreement, the Company agreed to issue to the investor a warrant to purchase up to 280,601 shares of common stock at an exercise price of $3.08 per share in a concurrent private placement.

 

On May 5, 2023, the offering was completed. At closing, the investor exercised the pre-funded warrant in full. Accordingly, the Company issued to the investor 280,601 shares of common stock and a warrant to purchase up to 280,601 shares of common stock at an exercise price of $3.08 per share for total gross proceeds of $899,326 and net proceeds of $751,933.

 

The warrant is exercisable for a period of 5.5 years at an initial exercise price of $3.08 per share and may be exercised on a cashless basis if at the time of exercise there is no effective registration statement registering the warrants, or the prospectus contained therein is not available for the resale of, the shares issuable upon exercise of the warrant. The exercise price is subject to customary adjustments in the event of stock splits, stock dividends, stock combinations and similar recapitalization transactions. The warrant also contains a beneficial ownership limitation which provides that the Company shall not effect any exercise, and a holder shall not have the right to exercise, any portion of the warrant to the extent that, after giving effect to the exercise, such holder (together with such holder’s affiliates) would beneficially own in excess of 4.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares issuable upon the exercise. This limitation may be waived (up to a maximum of 9.99%) by a holder in its sole discretion upon not less than sixty-one (61) days’ prior notice to the Company.

 

H.C. Wainwright & Co., LLC (the “Placement Agent”) acted as the exclusive placement agent in connection with this offering and received a cash fee equal to 7.5% of the gross proceeds of the offering and a management fee equal to 1% of the gross proceeds of the offering. The Company also agreed to reimburse the Placement Agent $30,000 for fees and expenses of its legal counsel and other out-of-pocket expenses and $15,950 for certain closing costs. In addition to the cash fees, the Company issued to the Placement Agent warrants to purchase up to 21,045 shares of common stock at an exercise price of $4.00625 per share (or 125% of the offering price).

 

Second Registered Direct Offering and Related Private Placement

 

On May 17, 2023, the Company entered into a securities purchase agreement with an institutional investor, pursuant to which the Company agreed to issue and sell, in a registered direct offering 206,000 shares of common stock and a pre-funded warrant to purchase up to 378,892 shares of common stock at an exercise price of $0.0001, at an offering price per share and pre-funded warrant of $2.71 and $2.7099, respectively. In addition, under the securities purchase agreement, the Company agreed to issue to the investor a warrant to purchase up to 584,892 shares of common stock at an exercise price of $2.59 per share in a concurrent private placement.

 

On May 19, 2023, the offering was completed. At closing, the investor exercised the pre-funded warrant in full. Accordingly, the Company issued to the investor 584,892 shares of common stock and a warrant to purchase up to 584,892 shares of common stock at an exercise price of $2.59 per share for total gross proceeds of $1,585,057 and net proceeds of $1,074,377.

 

The warrant is exercisable for a period of 5.5 years at an initial exercise price of $2.59 per share and may be exercised on a cashless basis if at the time of exercise there is no effective registration statement registering the warrants or the prospectus contained therein is not available for the resale of, the shares issuable upon exercise of the warrant. The exercise price is subject to customary adjustments in the event of stock splits, stock dividends, stock combinations and similar recapitalization transactions. The warrant also contains a beneficial ownership limitation which provides that the Company shall not effect any exercise, and a holder shall not have the right to exercise, any portion of the warrant to the extent that, after giving effect to the exercise, such holder (together with such holder’s affiliates) would beneficially own in excess of 4.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares issuable upon the exercise. This limitation may be waived (up to a maximum of 9.99%) by a holder in its sole discretion upon not less than sixty-one (61) days’ prior notice to us.

 

H.C. Wainwright & Co., LLC, the Placement Agent, acted as the exclusive placement agent in connection with this offering and received a cash fee equal to 7.5% of the gross proceeds of the offering and a management fee equal to 1% of the gross proceeds of the offering. The Company also agreed to reimburse the Placement Agent $60,000 for fees and expenses of its legal counsel and other out-of-pocket expenses and $15,950 for certain closing costs. In addition to the cash fees, the Company issued to the Placement Agent warrants to purchase up to 43,867 shares of common stock at an exercise price of $3.3875 per share (or 125% of the offering price).

 

Amendment to GSP License Agreement and Issuance of Common Stock

 

On April 7, 2023, the Company and GSP entered into the third amendment to license agreement with ABG-S1 LLC (“ABG”) to amend the license agreement, dated January 1, 2020, as amended on June 1, 2020 and August 1, 2021. Pursuant to the amendment, GSP agreed to make certain past due payments under the license agreement, as well as an additional cash fee, on the earlier of (i) the closing of the Company’s proposed financing, or (ii) April 15, 2023. As further consideration for ABG’s entry into the amendment, the Company issued 250,000 shares of common stock to ABG on April 17, 2023.

 

Conversion of Preferred Stock

 

On May 4, 2023, the Company issued 29,999 shares of common stock upon the conversion of 1,000 shares of series A convertible preferred stock.

 

 

SMART FOR LIFE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
THREE MONTHS ENDED MARCH 31, 2023 AND 2022

(UNAUDITED)

  

Amendments to Loan Agreements

 

On April 1, 2023, the Company entered into letter agreements with the holders of most of the secured subordinated promissory notes in the aggregate principal amount of $1,300,000 issued on July 29, 2022 in connection with the acquisition of Ceautamed (see Note 7), pursuant to which the Company agreed to pay the remaining balance of the notes in two payments on May 1, 2023 and June 1, 2023. In addition, the Company agreed to prepay a portion of the outstanding principal and accrued interest on the notes upon the occurrence of any of the following events: (i) in the event the Company receives any tax refunds claimed with respect to an “employee retention credit” pursuant to Section 2301 of the CARES Act (or any corresponding or similar provisions of state or local law) or receives any cash from factoring or assigning the right to receive such tax refunds, the Company must prepay $150,000 of the outstanding principal and accrued interest on the notes; (ii) in the event the Company or any its subsidiaries raise capital through the issuance of any convertible debentures, the Company must prepay the outstanding principal and accrued interest on the notes in an amount equal to one-third (1/3) of the net proceeds from such financing; and (iii) in the event the Company or any of its subsidiaries consummates an equity or equity-linked capital raise with the assistance of an investment bank, the Company must prepay the outstanding principal and accrued interest on the notes in an amount equal to one-third (1/3) of the proceeds raised by the Company or any of its subsidiaries, up to an aggregate amount of $350,000, plus any then overdue principal payments. The Company also agreed to pay certain amendment fees.

 

On April 20, 2023, the Company entered into a third amendment to the loan agreement with Diamond Creek Capital, LLC to amend the loan agreement, dated July 1, 2021, as amended on June 30, 2022 and December 29, 2022 (see Note 7). The amendment provides that the Company shall make a payment towards the reduction of principal in the amount of $250,000 within two business days of the earlier to occur of the following events: (i) the Company receives any tax refunds claimed with respect to an “employee retention credit” pursuant to Section 2301 of the CARES Act (or any corresponding or similar provisions of state or local law) or receives any cash from factoring or assigning the right to receive such tax refunds, or (ii) the completion of a public offering of securities pursuant to a Registration Statement on Form S-3. In addition, within two business days following the completion of a public offering of securities pursuant to a Registration Statement on Form S-1, the Company agreed to pay in full all outstanding amounts owing under the loan agreement. The amendment also provides that following the payment of $250,000 described above, monthly payments of principal and interest pursuant to shall be an aggregate of $30,000 per month, until the amounts owing under the loan agreement are paid in full. 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

The following discussion and analysis summarizes the significant factors affecting our operating results, financial condition, liquidity and cash flows as of and for the periods presented below. The following discussion and analysis should be read in conjunction with the financial statements and the related notes thereto included elsewhere in this report. The discussion contains forward-looking statements that are based on the beliefs of management, as well as assumptions made by, and information currently available to, our management. Actual results could differ materially from those discussed in or implied by forward-looking statements as a result of various factors, including those discussed below and elsewhere in this report.

 

Use of Terms

 

Except as otherwise indicated by the context and for the purposes of this report only, references in this report to “we,” “us,” “our” and “our company” are to Smart for Life, Inc., a Nevada corporation, and its consolidated subsidiaries.

 

Special Note Regarding Forward Looking Statements

 

This report contains forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts are forward-looking statements. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about:

 

	●	our goals and strategies;

	●	our future business development, financial condition and results of operations;

	●	expected changes in our revenue, costs or expenditures;

	●	growth of and competition trends in our industry;

	●	our expectations regarding demand for, and market acceptance of, our products;

	●	our expectations regarding our relationships with investors, institutional funding partners and other parties we collaborate with;

	●	fluctuations in general economic and business conditions in the markets in which we operate; and

●

relevant government policies and regulations relating to our industry.

 

In some cases, you can identify forward-looking statements by terms such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Item 1A “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2022 elsewhere in this report. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance.

 

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

 

The forward-looking statements made in this report relate only to events or information as of the date on which the statements are made in this report. Except as expressly required by the federal securities laws, there is no undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

 

 

Overview

 

We are engaged in the development, marketing, manufacturing, acquisition, operation and sale of a broad spectrum of nutritional and related products with an emphasis on health and wellness. Structured as a global holding company, we are executing a buy-and-build strategy with serial accretive acquisitions creating a vertically integrated company with an objective of aggregating companies generating a minimum of $300 million in revenues by the fourth quarter of 2026. To drive growth and earnings, we are developing proprietary products as well as acquiring other profitable companies, encompassing brands, manufacturing and distribution channels.

 

We also operate a network platform in the affiliate marketing space. Affiliate marketing is an advertising model in which a product vendor compensates third-party digital marketers to generate traffic or leads for the product vendor’s products and services. The third-party digital marketers are referred to as affiliates, and the commission fee incentivizes them to find ways to promote the products being sold by the product vendor.

 

On March 8, 2018, we acquired 51% of Millenium Natural Manufacturing Corp. and Millenium Natural Health Products Inc. and on October 9, 2019, we acquired the remaining 49% of these companies. On September 30, 2020, we changed the name of Millenium Natural Manufacturing Corp. to Bonne Sante Natural Manufacturing, Inc., or BSNM, and on November 24, 2020, we merged Millenium Natural Health Products Inc. into BSNM to better reflect our vertical integration. BSNM is a nutraceutical contract manufacturer. It specializes in a wide variety of products, from the private labeling of vitamins, dietary supplements, nutraceuticals, sport nutrition and broad-spectrum nutritional supplements, and sells them throughout the United States and around the world, including South America, Central America and Europe.

 

On July 1, 2021, we acquired 100% of Doctors Scientific Organica, LLC, Oyster Management Services, Ltd., Lawee Enterprises, L.L.C. and U.S. Medical Care Holdings, L.L.C. On August 27, 2021, we transferred all of the equity interests of Oyster Management Services, Ltd., Lawee Enterprises, L.L.C. and U.S. Medical Care Holdings, L.L.C. to Doctors Scientific Organica, LLC. On December 13, 2022, we converted Oyster Management Services, Ltd. to a limited liability company known as Oyster Management Services, L.L.C. On May 19, 2022, we acquired 100% of Lavi Enterprises, LLC, an affiliate of these companies. On the same date, we transferred all of the equity interests of Lavi Enterprises, LLC to Doctors Scientific Organica, LLC. As a result, these entities are now wholly owned subsidiaries of Doctors Scientific Organica, LLC. In this report, we collectively refer to Doctors Scientific Organica, LLC and its consolidated subsidiaries as DSO. DSO manufactures, sells and owns the Smart for Life brand of natural health and wellness meal replacement products. The brand includes proprietary hunger suppressing functional foods that are designed to work with the body’s natural ability to lose weight. It also develops premium supplements and commodities that will promote optimal health and wellness. DSO has over 15 years of experience providing high-quality products to premium retail locations and companies. Its branded vitamins and supplements are also being sold through Amazon, and this sales channel is becoming a major contributor to the growth of the brand online.

 

On August 24, 2021, we established Smart for Life Canada Inc. as a wholly owned subsidiary of DSO in Canada. This subsidiary sells retail products through a retail store location in Montreal Canada and the same location also acts as distribution center for our international direct to consumer and big box customers. We maintain inventory and employees at this location.

 

On November 8, 2021, we acquired 100% of Nexus Offers, Inc., or Nexus. Nexus operates a cost per action/cost per acquisition network. This network consists of hundreds of digital marketers who stand ready to market products introduced to the Nexus network. The cost per action/cost per acquisition model is where digital marketers are paid for an action (e.g., a product sale or lead generation) that is taken as a direct result of their marketing efforts. Through the digital marketer’s method of marketing, the digital marketer sends traffic to one of the product vendor’s offers listed on the network. 

 

On December 6, 2021, we acquired 100% of GSP Nutrition Inc., or GSP. GSP is a sports nutrition company. It offers nutritional supplements for athletes and active lifestyle consumers through a variety of wellness solutions and delivery methods, including powders, tablets and soft gels that are formulated to support energy and performance; nutrition and wellness; and focus and clarity. GSP’s initial line of nutritional products are marketed under the Sports Illustrated Nutrition brand. GSP has a license for the exclusive use of the Sports Illustrated brand (excluding the Sports Illustrated Swimsuit brand for which it has a right of first offer under the license) for certain dietary and nutritional supplements, in each case to be sold to/through certain approved accounts in the United States and Canada. The product line currently consists of whey protein isolate powder, tablet supplements for joint health, nitric oxide, post workout blends, Omega-3 supplements, and pre-workout supplements, among others.

 

 

On July 29, 2022, we acquired 100% of Ceautamed Worldwide, LLC and its wholly-owned subsidiaries Wellness Watchers Global, LLC and Greens First Female LLC (which we collectively refer to as Ceautamed). Ceautamed is based in Boca Raton, Florida and owns the Greens First line of branded products which have been specifically marketed to the healthcare provider sector. These vitamins and supplements have been sold on a business-to-business basis, direct-to-consumer as well as sold utilizing an international medical distribution company pursuant to a long-term contract. Ceautamed has historically utilized third-party contract manufacturing that will migrate to BSNM. 

 

Recent Developments

 

Conversion to Nevada and Increase in Authorized Stock

 

On April 10, 2023, we converted from a Delaware corporation to a Nevada corporation by filing: (i) a certificate of conversion with the Secretary of State of the State of Delaware; (ii) articles of conversion with the Secretary of State of the State of Nevada; and (iii) articles of incorporation with the Secretary of State of the State of Nevada. We also filed a certificate of designation for our series A convertible preferred stock with the Secretary of State of the State of Nevada and adopted new bylaws. At the time of the conversion:

 

●

our company’s domicile changed from the State of Delaware to the State of Nevada;

 

●

our affairs ceased to be governed by the General Corporation Law of the State of Delaware and our prior certificate of incorporation and bylaws, and instead became governed by the Nevada Revised Statutes and the articles of incorporation and new bylaws;

 

●

our company continued to be the same entity and continues with all of the same rights, privileges and powers;

 

●

our company continued to have the same name, possesses all of the same properties, continued with all of debts, liabilities and obligations, and continued with the same officers and directors as immediately prior to the conversion;

 

●

the number of shares of common stock that we are authorized to issue increased from 100 million shares to 500 million shares;

 

●

each outstanding share of the common stock, series A convertible preferred stock, warrants to purchase shares of common stock and other convertible securities of our company previously incorporated in Delaware, or SMFL Delaware, automatically converted into one share of common stock, one share of series A convertible preferred stock and an equivalent number of convertible securities of our company incorporated in Nevada, or SMFL Nevada, with the same price per share, upon the same terms and subject to the same conditions as before the conversion, and certificates issued for shares of SMFL Delaware’s common stock and series A convertible preferred stock prior to the conversion automatically came to represent shares of SMFL Nevada’s common stock and series A convertible preferred stock upon completion of the conversion; and

 

●

our employee benefit and incentive plans continued, and each option, equity award or other right of SMFL Delaware issued under such plans automatically converted into an option, equity award or right to purchase or receive the same number of shares of common stock of SMFL Nevada, at the same price per share, upon the same terms and subject to the same conditions as before the conversion.

 

Reverse Stock Split

 

On April 24, 2023, we effected a 1-for-50 reverse stock split. As a result of this reverse split, our issued and outstanding common stock decreased from 40,440,129 shares to 822,303 shares. The impact of this transaction is reflected within all common stock, options, and warrant information in this report.

 

Registered Direct Offering and Related Private Placement

 

On May 2, 2023, we entered into a securities purchase agreement with an institutional investor, pursuant to which we agreed to issue and sell, in a registered direct offering, 94,600 shares of common stock and a pre-funded warrant to purchase up to 186,001 shares of common stock at an exercise price of $0.0001, at an offering price per share and pre-funded warrant of $3.205 and $3.2049, respectively. In addition, under the securities purchase agreement, we agreed to issue to the investor a warrant to purchase up to 280,601 shares of common stock at an exercise price of $3.08 per share in a concurrent private placement.

 

 

On May 5, 2023, the offering was completed. At closing, the investor exercised the pre-funded warrant in full. Accordingly, we issued to the investor 280,601 shares of common stock and a warrant to purchase up to 280,601 shares of common stock at an exercise price of $3.08 per share for total gross proceeds of $899,326 and net proceeds of $751,933.

 

The warrant is exercisable for a period of 5.5 years at an initial exercise price of $3.08 per share and may be exercised on a cashless basis if at the time of exercise there is no effective registration statement registering the warrants, or the prospectus contained therein is not available for the resale of, the shares issuable upon exercise of the warrant. The exercise price is subject to customary adjustments in the event of stock splits, stock dividends, stock combinations and similar recapitalization transactions. The warrant also contains a beneficial ownership limitation which provides that we shall not effect any exercise, and a holder shall not have the right to exercise, any portion of the warrant to the extent that, after giving effect to the exercise, such holder (together with such holder’s affiliates) would beneficially own in excess of 4.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares issuable upon the exercise. This limitation may be waived (up to a maximum of 9.99%) by a holder in its sole discretion upon not less than sixty-one (61) days’ prior notice to us.

 

H.C. Wainwright & Co., LLC, the Placement Agent, acted as the exclusive placement agent in connection with this offering and received a cash fee equal to 7.5% of the gross proceeds of the offering and a management fee equal to 1% of the gross proceeds of the offering. We also agreed to reimburse the Placement Agent $30,000 for fees and expenses of its legal counsel and other out-of-pocket expenses and $15,950 for certain closing costs. In addition to the cash fees, we issued to the Placement Agent warrants to purchase up to 21,045 shares of common stock at an exercise price of $4.00625 per share (or 125% of the offering price).

 

Second Registered Direct Offering and Related Private Placement

 

On May 17, 2023, we entered into a securities purchase agreement with an institutional investor, pursuant to which we agreed to issue and sell, in a registered direct offering 206,000 shares of common stock and a pre-funded warrant to purchase up to 378,892 shares of common stock at an exercise price of $0.0001, at an offering price per share and pre-funded warrant of $2.71 and $2.7099, respectively. In addition, under the securities purchase agreement, we agreed to issue to the investor a warrant to purchase up to 584,892 shares of common stock at an exercise price of $2.59 per share in a concurrent private placement.

 

On May 19, 2023, the offering was completed. At closing, the investor exercised the pre-funded warrant in full. Accordingly, we issued to the investor 584,892 shares of common stock and a warrant to purchase up to 584,892 shares of common stock at an exercise price of $2.59 per share for total gross proceeds of $1,585,057 and net proceeds of $1,074,377.

 

The warrant is exercisable for a period of 5.5 years at an initial exercise price of $2.59 per share and may be exercised on a cashless basis if at the time of exercise there is no effective registration statement registering the warrants or the prospectus contained therein is not available for the resale of, the shares issuable upon exercise of the warrant. The exercise price is subject to customary adjustments in the event of stock splits, stock dividends, stock combinations and similar recapitalization transactions. The warrant also contains a beneficial ownership limitation which provides that we shall not effect any exercise, and a holder shall not have the right to exercise, any portion of the warrant to the extent that, after giving effect to the exercise, such holder (together with such holder’s affiliates) would beneficially own in excess of 4.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares issuable upon the exercise. This limitation may be waived (up to a maximum of 9.99%) by a holder in its sole discretion upon not less than sixty-one (61) days’ prior notice to us.

 

H.C. Wainwright & Co., LLC, the Placement Agent, acted as the exclusive placement agent in connection with this offering and received a cash fee equal to 7.5% of the gross proceeds of the offering and a management fee equal to 1% of the gross proceeds of the offering. We also agreed to reimburse the Placement Agent $60,000 for fees and expenses of its legal counsel and other out-of-pocket expenses and $15,950 for certain closing costs. In addition to the cash fees, we issued to the Placement Agent warrants to purchase up to 43,867 shares of common stock at an exercise price of $3.3875 per share (or 125% of the offering price).

 

Amendments to Loan Agreements

 

On April 1, 2023, we entered into letter agreements with the holders of most of the secured subordinated promissory notes in the aggregate principal amount of $1,300,000 issued on July 29, 2022 in connection with the acquisition of Ceautamed described below, pursuant to which we agreed to pay the remaining balance of the notes in two payments on May 1, 2023 and June 1, 2023. In addition, we agreed to prepay a portion of the outstanding principal and accrued interest on the notes upon the occurrence of any of the following events: (i) in the event we receive any tax refunds claimed with respect to an “employee retention credit” pursuant to Section 2301 of the Coronavirus Aid, Relief and Economic Security Act, or the CARES Act  (or any corresponding or similar provisions of state or local law) or receives any cash from factoring or assigning the right to receive such tax refunds, we must prepay $150,000 of the outstanding principal and accrued interest on the notes; (ii) in the event we raise capital through the issuance of any convertible debentures, we must prepay the outstanding principal and accrued interest on the notes in an amount equal to one-third (1/3) of the net proceeds from such financing; and (iii) in the event we consummate an equity or equity-linked capital raise with the assistance of an investment bank, we must prepay the outstanding principal and accrued interest on the notes in an amount equal to one-third (1/3) of the proceeds raised by us, up to an aggregate amount of $350,000, plus any then overdue principal payments. We also agreed to pay certain amendment fees.

 

On April 20, 2023, we entered into a third amendment to the loan agreement with Diamond Creek Capital, LLC to amend the loan agreement, dated July 1, 2021, as amended on June 30, 2022 and December 29, 2022, described below. The amendment provides that we shall make a payment towards the reduction of principal in the amount of $250,000 within two business days of the earlier to occur of the following events: (i) we receive any tax refunds claimed with respect to an “employee retention credit” pursuant to Section 2301 of the CARES Act (or any corresponding or similar provisions of state or local law) or any cash from factoring or assigning the right to receive such tax refunds, or (ii) the completion of a public offering of securities pursuant to a Registration Statement on Form S-3. In addition, within two business days following the completion of a public offering of securities pursuant to a Registration Statement on Form S-1, we agreed to pay in full all outstanding amounts owing under the loan agreement. The amendment also provides that following the payment of $250,000 described above, monthly payments of principal and interest pursuant to shall be an aggregate of $30,000 per month, until the amounts owing under the loan agreement are paid in full.

 

Principal Factors Affecting Our Financial Performance

 

Our operating results are primarily affected by the following factors:

 

●

our ability to acquire new customers or retain existing customers;

 

●

our ability to offer competitive product pricing;

 

●

our ability to broaden product offerings;

 

●

industry demand and competition; and

 

●

market conditions and our market position.

 

Emerging Growth Company

 

We qualify as an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As a result, we will be permitted to, and intend to, rely on exemptions from certain disclosure requirements. For so long as we are an emerging growth company, we will not be required to:

 

●

have an auditor report on our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act;

 

●

comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (i.e., an auditor discussion and analysis);

 

●

submit certain executive compensation matters to stockholder advisory votes, such as “say-on-pay” and “say-on-frequency;” and

 

●

disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the chief executive officer’s compensation to median employee compensation.

 

In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards.

 

We will remain an emerging growth company until the earliest of (i) the last day of the fiscal year following the fifth anniversary of our initial public offering, or the IPO, (ii) the last day of the first fiscal year in which our total annual gross revenues are $1.07 billion or more, (iii) the date that we become a “large accelerated filer” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur if the market value of our common stock that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter or (iv) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three year period.

 

 

Results of Operations

 

Comparison of Three Months Ended March 31, 2023 and 2022

 

The following table sets forth key components of our results of operations during the three months ended March 31, 2023 and 2022, both in dollars and as a percentage of our revenues.

 

		March 31, 2023								March 31, 2022
		Amount				% of Revenues				Amount				% of Revenues
Revenues
Products		$	2,059,712				85.66	%		$	3,575,459				80.26	%
Advertising			344,855				14.34	%			879,427				19.74	%
Total revenues			2,404,567				100.00	%			4,454,886				100.00	%
Cost of revenues
Products			1,307,444				54.37	%			2,297,010				51.56	%
Advertising			269,394				11.20	%			640,313				14.37	%
Total cost of revenues			1,576,838				65.58	%			2,937,323				65.93	%
Gross profit			827,729				34.42	%			1,517,563				34.07	%
Operating expenses
General and administrative			1,095,207				45.55	%			1,721,855				38.65	%
Compensation - administrative			1,472,374				61.23	%			2,003,835				44.98	%
Professional services			303,996				12.64	%			640,731				14.38	%
Consulting fees - related parties			(27,547	)			(1.15	)%			—				—
Depreciation and amortization expense			691,210				28.75	%			423,010				9.50	%
Total operating expenses			3,590,334				149.31	%			4,789,431				107.51	%
Operating loss			(2,762,605	)			(114.89	)%			(3,271,868	)			(73.44	)%
Other income (expenses)
Other income (expense)			23,152				0.96	%			(506,133	)			(11.36	)%
Change in fair value of derivative liability			—				—				(38,997	)			(0.88	)%
Interest expense			(1,544,862	)			(64.25	)%			(12,757,479	)			(286.37	)%
Total other income (expenses)			(1,521,710	)			(63.28	)%			(13,302,609	)			(298.61	)%
Net loss		$	(4,284,315	)			(178.17	)%		$	(16,574,477	)			(372.05	)%

 

Revenues. Our total revenues decreased by $2,050,319, or 46.02%, to $2,404,567 for the three months ended March 31, 2023 from $4,454,886 for the three months ended March 31, 2022.

 

Our nutraceutical business generates revenue from the sales of nutritional and related products. Revenues from our nutraceutical business (products) decreased by $1,515,747, or 42.39%, to $2,059,712 for the three months ended March 31, 2023 from $3,575,459 for the three months ended March 31, 2022. This decrease was primarily due to our cash constraints and our inability to pay for raw materials used in the production of both branded and contract manufacturing products. The decreased revenues were the result of a decrease in the volume of products sold and not due to pricing changes.

 

Our digital marketing business generates revenues when sales of listed products are sold by product vendors through our network as a result of the marketing efforts of digital marketers. Revenues from our digital marketing business (advertising) decreased by $534,572, or 60.79%, to $344,855 for the three months ended March 31, 2023 from $879,427 for the three months ended March 31, 2022. The decrease in revenue is attributable to our cash constraints and the impact it had with our affiliate advertisers.

 

Cost of revenues. Our total cost of revenues decreased by $1,360,485, or 46.32%, to $1,576,838 for the three months ended March 31, 2023 from $2,937,323 for the three months ended March 31, 2022. Such decrease is directly related to the decrease in revenues.

 

Cost of revenues for our nutraceutical business consist of ingredients, packaging materials, freight, and labor associated with the production of various products. Cost of revenues for our nutraceutical business (products) decreased by $989,566, or 43.08%, to $1,307,444 for the three months ended March 31, 2023 from $2,297,010 for the three months ended March 31, 2022. As a percentage of product revenues, cost of revenues for product sales were consistent at 63.48% and 64.24% for the three months ended March 31, 2023 and 2022, respectively.

 

 

Cost of revenues for our digital marketing business consist of commissions and bonuses paid to digital marketers. Cost of revenues from our digital marketing business (advertising) decreased by $370,919, or 57.93%, to $269,394 for the three months ended March 31, 2023 from $640,313 for the three months ended March 31, 2022. As a percentage of advertising revenues, cost of revenues for advertising sales was 78.12% and 72.81% for the three months ended March 31, 2023 and 2022, respectively.

 

Gross profit. As a result of the foregoing, our gross profit decreased by $689,834, or 45.46%, to $827,729 for the three months ended March 31, 2023 from $1,517,563 for the three months ended March 31, 2022. As a percentage of revenues, our gross profit was 34.42% and 34.07% for the three months ended March 31, 2023 and 2022, respectively.

 

General and administrative expenses.  Our general and administrative expenses consist primarily of advertising expenses, bad debts, rent expense, insurance and other expenses incurred in connection with general operations. Our general and administrative expenses decreased by $626,648, or 36.39%, to $1,095,207 for the three months ended March 31, 2023 from $1,721,855 for the three months ended March 31, 2022. Such decrease was primarily due to decreased rates for D&O Insurance, IPO related expenses in February 2022 and reduced advertising in 2023. As a percentage of revenues, general and administrative expenses was 45.55% and 38.65% for the three months ended March 31, 2023 and 2022, respectively.

 

Compensation - administrative.  Our compensation expenses include both cash and non-cash items, including salaries plus related payroll taxes. Our compensation expenses decreased by $531,461, or 26.52%, to $1,472,374 for the three months ended March 31, 2023 from $2,003,835 for the three months ended March 31, 2022. Such decrease was primarily due to reduced stock compensation expense in 2023 and a reduction of headcount. As a percentage of revenues, compensation expenses was 61.23% and 44.98% for the three months ended March 31, 2023 and 2022, respectively.

 

Professional services.  Our professional services expenses consist primarily of investor relations, consulting, advisory, legal and audit expenses incurred in connection with general operations. Our professional services expenses decreased by $336,735, or 52.55%, to $303,996 for the three months ended March 31, 2023 from $640,731 for the three months ended March 31, 2022. Such decrease was primarily due to IPO expenses in 2022. As a percentage of revenues, professional services expenses was 12.64% and 14.38% for the three months ended March 31, 2023 and 2022, respectively.

 

Consulting fees – related parties.  For the three months ended March 31, 2023 and 2022, we paid Trilogy Capital Group, LLC, a company controlled by our Executive Chairman, $27,547 and $0, respectively, for services rendered under a consulting agreement.

 

Depreciation and amortization. Depreciation and amortization was $691,210, or 28.75% of revenues, for the three months ended March 31, 2023, as compared to $423,010, or 9.50% of revenues, for the three months ended March 31, 2023. The increase in amortization is associated with intangible assets resulting from the acquisitions.

 

Total other expense. We had $1,521,710 in total other expense, net, for the three months ended March 31, 2023, as compared to total other expense, net, of $13,302,609 for the three months ended March 31, 2022. Total other expense, net, for the three months ended March 31, 2023 consisted of interest expense of $1,544,862, offset by other income of $23,152, while other expense, net, for the three months ended March 31, 2022 consisted of interest expense of $12,757,479 related to interest expense in connection with common stock issued with future equity agreements and amortization of debt issuance cost, other expense of $506,133 and change in fair value of derivative liability of $38,997. 

 

Net loss. As a result of the cumulative effect of the factors described above, we had a net loss of $4,284,315 for the three months ended March 31, 2023, as compared to $16,574,477 for the three months ended March 31, 2022, a decrease of $12,290,162, or 74.15%.

 

Liquidity and Capital Resources

 

As of March 31, 2023, we had cash of $86,194. To date, we have financed our operations primarily through revenue generated from operations, bank borrowings and sales of our securities. Since our inception in 2017, we have experienced losses and as a result have continued to use cash in our operations. We have been dependent upon financing activities as we implement our acquisition strategy.

 

Our consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. We have suffered recurring losses from operations and have a working capital deficiency of $15.0 million.  These conditions raise substantial doubt about our ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

 

Management believes that current available resources will not be sufficient to fund our planned expenditures over the next 12 months from the date hereof. Accordingly, we will be dependent upon the raising of additional capital through placement of common stock and/or debt financing in order to implement our business plan. There is no assurance that we will be successful with future financing ventures, and the inability to secure such financing may have a material adverse effect on our financial condition.

 

Summary of Cash Flow

 

The following table provides detailed information about our net cash flow for the three months ended March 31, 2023 and 2022.

 

		Three Months Ended March 31,
		2023				2022
Net cash used in operating activities		$	(378,715	)		$	(4,212,202	)
Net cash used in investing activities			—				(15,963	)
Net cash provided by financing activities			395,195				5,574,127
Increase in cash			16,480				1,345,962
Cash and cash equivalents at beginning of period			69,714				205,093
Cash and cash equivalents at end of period		$	86,194			$	1,551,055

 

Our net cash used in operating activities was $378,715 for the three months ended March 31, 2023, as compared to $4,212,202 for the three months ended March 31, 2022. For the three months ended March 31, 2023, our net loss of $4,284,315, offset by debt issuance cost of $728,544, depreciation and amortization of $691,210, an increase in accounts payable of $685,265, and a decrease in inventory of $570,289 were the primary drivers for cash used in operations. For the three months ended March 31, 2022, our net loss of $16,574,477 and non-cash finance expense associated with future equity agreements of approximately $10,844,961, were the primary drivers for cash used in operations.

 

We had no investing activities for the three months ended March 31, 2023. For the three months ended March 31, 2022, our net cash used in investing activities was $15,963, which consisted of equipment purchases.

 

Our net cash provided by financing activities was $395,195 for the three months ended March 31, 2023, as compared to $5,574,127 for the three months ended March 31, 2022. Net cash provided by financing activities for the three months ended March 31, 2023 consisted of proceeds from debt of $1,409,000, receipts from related parties of $12,700 and proceeds from the exercise of warrants of $119, offset by repayments on debt of $1,026,624, while net cash provided by financing activities for the three months ended March 31, 2021 consisted of net proceeds from the IPO of $12,738,288, proceeds from convertible notes and notes payable of $783,738 and proceeds from related parties of $344,873, offset by repayments of convertible notes and notes payable of $6,924,841, repayments to related parties of $1,314,382 and payment of fees from issuance of common stock of $53,549.

 

Initial Public Offering

 

On February 16, 2022, we entered into an underwriting agreement with Dawson James Securities, Inc., as representative of the several underwriters named on Schedule I thereto, relating to our IPO of units, each unit consisting of one share of common stock, a series A warrant to purchase one share of common stock and a series B warrant to purchase one share of common stock. Pursuant to the underwriting agreement, we agreed to sell 28,800 units to the underwriters, at a purchase price per unit of $455.00 (the offering price to the public of $500.00 per unit minus the underwriters’ discount), and also agreed to grant to the underwriters a 45-day option to purchase up to 4,320 additional shares of common stock, up to 4,320 additional series A warrants, and/or up to 4,320 additional series B warrants, in any combination thereof, at a purchase price to the public of $499.00 per share and $0.50 per warrant, less underwriting discounts and commissions, solely to cover over-allotments, if any.

 

On February 18, 2022, the closing of our IPO was completed. At the closing, the underwriters partially exercised the option and purchased 4,128 series A warrants and 4,128 series B warrants. Therefore, we sold 28,800 shares of common stock, 32,928 series A warrants and 32,928 series B warrants for total gross proceeds of $14,404,128. After deducting the underwriting commission and expenses, we received net proceeds of approximately $12,684,739. We used the proceeds of the offering to pay off certain debt and plan to use the remaining net proceeds for working capital and general corporate purposes.

 

 

The series A warrants are exercisable until the fifth anniversary of the issuance date at an exercise price equal to $350.00 per share and may be exercised on a cashless basis if the issuance of common stock upon exercise of the warrants is not covered by an effective registration statement.

 

The series B warrants are exercisable until the fifth anniversary of the issuance date at an exercise price equal to $500.00 per share and may be exercised on a cashless basis, whereby the holder will receive one share of common stock for each series B warrant exercised. As of March 31, 2023, 28,785 of the series B warrants were exercised on a cashless basis and we issued 28,785 shares of common stock upon such exercise.

 

Outstanding Debt

 

Original Issue Discount Subordinated Debentures

 

In June 2022, we commenced offerings of original issue discount subordinated debentures. As of March 31, 2023, we have completed multiple closings and issued debentures in the aggregate principal amount of $4,764,099, of which $847,060 was issued with issuances costs of $127,060 for the three months ended March 31, 2023. The debentures contain an original issue discount of 15%, or an aggregate original issue discount of $713,830. As a result, the total purchase price was $4,050,270. The debentures bear interest at a rate of 17.5% per annum and are due from January through November 2024. The outstanding principal amount and all accrued interest is due and payable on the earlier of (i) the completion of our next equity financing in which we receive gross proceeds in excess of $20 million, (ii) twenty-four months after the date of issuance or (iii) within 30 days after election of repayment from the holder so long as the election is after the 6-month anniversary of the debenture. We may voluntarily prepay the debentures in whole or in part without premium or penalty. The debentures contain customary events of default for a loan of this type. The debentures are unsecured and are subordinated in right of payment to the prior payment in full of all senior indebtedness and are pari passu in right of payment to any other unsecured indebtedness incurred by our company in favor of any third party. As of March 31, 2023, the outstanding principal balance of the debentures was $4,758,830, the unamortized debt issuance cost was $367,399 and accrued interest was $483,768.

 

Original Issue Discount Secured Subordinated Note

 

On July 29, 2022, we entered into a securities purchase agreement with an accredited investor, pursuant to which we sold an original issue discount secured subordinated note in the principal amount of $2,272,727 to such investor. The note contains an original issue discount of 12%, or an original issue discount of $272,727. As a result, the total purchase price was $2,000,000, the proceeds of which were used to fund the acquisition of Ceautamed. The note shall bear interest at the rate of 16% per annum and matures on July 29, 2027. The outstanding principal and all accrued interest shall be amortized on a 60-month straight-line basis and payable in accordance with the amortization schedule set forth on Exhibit A to the note. We may prepay the principal and all accrued and unpaid interest on the note without penalty, in whole or in part; provided however, in no event before January 15, 2023, unless with the explicit prior written approval of the holder. The note contains customary events of default for a loan of this type. The note is guaranteed by BSNM, DSO, Nexus, GSP and Ceautamed and is secured by a security interest in all of the assets of our company and such guarantors; provided that such security interest is subordinate to the rights of the lenders under any senior indebtedness (as defined in the note). As of March 31, 2023, the outstanding principal balance of the note was $2,212,177, the unamortized debt issuance cost was $213,880 and accrued interest was $89,714.

 

Acquisition Notes

 

On July 1, 2021, we issued a 6% secured subordinated promissory note in the principal amount of $3,000,000 to Sasson E. Moulavi in connection with the acquisition of DSO. This note accrues interest at 6% per annum with the outstanding principal and interest amortized on a straight-line basis and payable quarterly in accordance with the amortization schedule attached to the note, with all amounts due and payable on July 1, 2024. On November 29, 2022, we entered into a letter agreement with Sasson E. Moulavi to amend the terms of the note. Pursuant to the letter agreement, the parties agreed to amend and restate the note to amend the amortization schedule attached thereto, with the first payment deferred until February 15, 2023 and all amounts due and payable on August 15, 2024. In exchange for the agreement of Dr. Moulavi to enter into the letter agreement, we agreed to (i) issue to Dr. Moulavi 100,000 shares of common stock under our 2022 Equity Incentive Plan and (ii) pay to Dr. Moulavi a fee of $50,000 in cash, which shall be paid upon completion of our anticipated debt financing. We may prepay all or any portion of this note any time prior to maturity without premium or penalty. This note contains customary covenants and events of default for a loan of this type, including if a default occurs under any senior secured indebtedness to banks and other financial institutions or private equity funds, and is secured by a security interest in all of the assets of DSO; provided that such security interest is subordinate to the rights of the lenders under any such senior secured indebtedness. As of March 31, 2023, the outstanding principal balance of this note was $3,050,000 and accrued interest was $324,317.

 

 

On November 8, 2021, we issued a 5% secured subordinated promissory note in the principal amount of $1,900,000 to Justin Francisco and Steven Rubert in connection with the acquisition of Nexus. This note accrues interest at 5% per annum and the outstanding principal and interest will be amortized on a straight-line basis and are payable quarterly in accordance with the amortization schedule attached to the note, with all amounts due and payable on November 8, 2024. We may prepay all or any portion of this note any time prior to maturity without premium or penalty. The note contains customary covenants and events of default for a loan of this type, including if a default occurs under any senior secured indebtedness to banks and other financial institutions or private equity funds, and is secured by a security interest in all of our assets; provided that such security interest is subordinate to the rights of the lenders under any such senior secured indebtedness. As of March 31, 2023, the outstanding principal balance of this note was $1,900,000 and accrued interest was $134,056.

 

On July 29, 2022, we issued secured subordinated convertible promissory notes in the aggregate principal amount of $2,150,000 in connection with the acquisition of Ceautamed. The notes shall bear interest at the rate of 5% per annum with all principal and accrued interest being due and payable in one lump sum on July 29, 2025; provided that upon an event of default (as defined in the notes), such interest rate shall increase to 10%. The notes are convertible at the option of the holder into common stock at a conversion price of $6.25; provided that the holder may not elect to convert a portion of the outstanding principal in an amount less than the lesser of $200,000 or the remaining outstanding principal. The notes contain customary covenants and events of default for loans of this type, including upon any default under the senior indebtedness (as defined in the notes). The notes are guaranteed by Ceautamed and its subsidiaries and are secured by a security interest in all of the assets of such guarantors; provided that such security interest is subordinate to the rights of the lenders under any such senior indebtedness. As of March 31, 2023, the outstanding principal balance of these notes was $2,150,000 and accrued interest was $73,160.

 

On July 29, 2022, we issued secured subordinated promissory notes in the aggregate principal amount of $2,150,000 in connection with the acquisition of Ceautamed. The notes shall bear interest at the rate of 5% per annum and mature on July 29, 2025; provided that upon an event of default (as defined in the notes), such interest rate shall increase to 10%. The outstanding principal and all accrued interest shall be amortized on a five-year straight-line basis and payable in accordance with the amortization schedule set forth on Exhibit A to the notes. We may redeem all or any portion of the notes at any time without premium or penalty. The notes contain customary covenants and events of default for loans of this type, including upon any default under the senior indebtedness (as defined in the notes). The notes are guaranteed by Ceautamed and its subsidiaries and are secured by a security interest in all of the assets of such guarantors; provided that such security interest is subordinate to the rights of the lenders under any such senior indebtedness. As of March 31, 2023, the outstanding principal balance of these notes was $2,204,993, unamortized debt issuance cost was $54,993 and accrued interest was $75,031.

 

On July 29, 2022, we issued secured subordinated promissory notes in the aggregate principal amount of $1,300,000 in connection with the acquisition of Ceautamed. The notes bore interest at the rate of 5% per annum with all principal and accrued interest being due and payable in one lump sum ninety (90) days from the date of the note; provided that upon an event of default (as defined in the notes), such interest rate shall increase to 10%. On November 28, 2022, we entered into letter agreements with the holders of most of the notes to amend the terms of these notes. Pursuant to letter agreements, the parties agreed to extend the maturity date to June 1, 2023 and agreed to a seven month payment schedule, with the first payment due December 1, 2022. The parties also agreed to increase the default interest rate from 10% to 15%. We also agreed that if an event of default (as defined in the notes) has occurred and is continuing, then we shall not create any senior indebtedness (as defined in the notes) without the consent of the holders of a majority of the principal amount of the notes. In exchange for the agreement of the holders to enter into the letter agreements, we agreed to pay certain amendment fees as more particularly described in the letter agreements. We are in the process of negotiating a similar extension of one remining note in the principal amount of $100,000. We may redeem all or any portion of the notes at any time without premium or penalty. The notes contain customary covenants and events of default for loans of this type, including upon any default under the senior indebtedness (as defined in the notes). The notes are guaranteed by Ceautamed and its subsidiaries and are secured by a security interest in all of the assets of such guarantors; provided that such security interest is subordinate to the rights of the lenders under any such senior indebtedness. As of March 31, 2023, the outstanding principal balance of these notes was $1,148,000, unamortized debt issuance cost was $108,000 and accrued interest was $92,011.

 

Promissory Notes

 

On July 1, 2021, we entered into a loan agreement with Diamond Creek Capital, LLC for a term loan in the principal amount of up to $3,000,000. The loan bears interest at a rate of 15.0% per annum, provided that upon an event of default, such rate shall increase by 5%. The loan was due and payable on the earlier of July 1, 2022 or upon completion of the IPO. We repaid $1,325,000 of the principal balance and $27,604 of the interest from the proceeds of the IPO. In connection with such repayment, the lender agreed that the remaining loan is due and payable on July 1, 2023. The loan is secured by all of our assets and contains customary events of default. As of March 31, 2023, the outstanding principal balance of this note was $1,075,000 and accrued interest was $69,475.

 

 

In 2018, we entered into an amended loan agreement and convertible promissory note for $200,000 with a third party. On March 31, 2023, the outstanding amount was $200,000 and accrued interest was $155,484. 

 

In October 12, 2022, we issued promissory notes in the principal amount of $258,000 to third parties. These promissory notes bear interest of 15% to 20% and payable on December 2022 and January 2023. As of March 31, 2023, the outstanding principal balance was $258,000 and accrued interest was $9,371.

 

On November 2, 2022, we issued a promissory note to a board member in the principal amount of $50,000. This note bears interest at a rate of 12% and is due on demand. At March 31, 2023, the outstanding amount was $20,000 and accrued interest was $605.

 

On December 6, 2022, we issued a promissory note to a board member in the principal amount of $30,000. This note bears interest at a rate of 12% and is due on demand. At March 31, 2023, the outstanding amount was $30,000 and accrued interest was $1,150.

 

On December 21, 2022, we issued a promissory note to a board member in the principal amount of $100,000. This note bears interest at a rate of 12% and is due on demand. At March 31, 2023, the outstanding amount was $100,000 and accrued interest was $3,333.

 

On February 8, 2023, we issued a promissory note to a board member in the principal amount of $50,000. This note bears interest at a rate of 12% and is due on demand. At March 31, 2023, the outstanding amount was $50,000 and accrued interest was $850.

 

On February 14, 2023, we issued a promissory note to a third party in the principal amount of $50,000. This note bears interest at a rate of 12% and is due on demand. At March 31, 2023, the outstanding amount was $50,000 and accrued interest was $740. 

 

On February 16, 2023, we issued a promissory note to a third party in the principal amount of $50,000. This note bears interest at a rate of 12% and is due on August 26, 2023. At March 31, 2023, the outstanding amount was $50,000 and accrued interest was $658.

 

On March 7, 2023, we issued a promissory note to a board member in the principal amount of $137,000. This note bears interest at a rate of 12% and is due on demand. At March 31, 2023, the outstanding amount was $137,000 and accrued interest was $977.

 

Cash Advances

 

In June 2022, we entered into a cash advance agreement for $341,150 with a required repayment amount of $490,000, which requires weekly payments of approximately $19,738. At March 31, 2023, the outstanding amount was $22,124.

 

In July 2022, we entered into a cash advance agreement for $650,000 with a required repayment amount of $897,750, which requires weekly payments of approximately $40,806. At March 31, 2023, the outstanding amount was $474,690.

 

In August 2022, we entered into a cash advance agreement for $100,000 with a required repayment amount of $146,260, which requires weekly payments of approximately $6,200. At March 31, 2023, the outstanding amount was $4,360.

 

In September 2022, we entered into a cash advance agreement for $243,750 with a required repayment amount of $372,500, which requires weekly payments of approximately $15,000. At March 31, 2023, the outstanding amount was $232,500.

 

In November 2022, we entered into cash advance agreements for $592,236 with a required repayment amount of $994,460, which requires weekly payments of approximately $52,422. At March 31, 2023, the outstanding amount was $497,296.

 

In December 2022, we entered into cash advance agreements for $293,000 with a required repayment amount of $439,207, which requires weekly payments of approximately $39,905. At March 31, 2023, the outstanding amount was $81,271.

 

In January 2023, we entered into cash advance agreements for $321,000 with a required repayment amount of $593,604, which requires weekly payments of approximately $39,980. At March 31, 2023, the outstanding amount was $542,934.

 

Equipment Financing Loans

 

In May 2022, we entered into an equipment financing loan for $146,765 used for the purchase of equipment within BSNM’s operations. The loan bears interest at 10.18% and matures on April 1, 2027. At March 31, 2023, the outstanding amount was $127,152.

 

 

In August 2022, we entered into an equipment financing loan for $35,050 used for the purchase of equipment within BSNM’s operations. The loan bears interest at 10.18% and matures on August 1, 2027. At March 31, 2023, the outstanding amount was $32,167.

 

In July 2022, we entered into an equipment financing loan for $8,463 used for the purchase of equipment within Ceautamed’s operations. At March 31, 2023, the outstanding amount was $6,412.

 

Revolving Lines of Credit

 

In 2021, DSO entered into two revolving lines of credit with a bank, which permit borrowings up to $1,176,000, and bear interest at 8.99% and 7.99%. As of March 31, 2023, the outstanding principal balance of these lines of credit was $412,184. 

 

In August 2022, Ceautamed entered into a revolving line of credit with a bank, which permit borrowing up to $60,000, and bear interest at 45.09%. As of March 31, 2023, the outstanding principal balance of this line of credit was $48,556. 

 

In September 2022, DSO entered into a revolving line of credit with a bank, which permit borrowings up to $70,000, and bear interest at 9.49%. As of March 31, 2023, the outstanding principal balance of this line of credit was $38,671. 

 

EIDL Loan

 

In June 2020, pursuant to the economic injury disaster loan, or EIDL, program under the under the provisions of the CARES Act, we entered into a promissory note with the U.S. Small Business Administration, or the SBA, with a principal amount of $300,000. This loan matures in 30 years and bears interest at a rate of 3.75%. The loan is secured by all of our assets. As of March 31, 2023, the outstanding principal balance of this loan was $300,000 and accrued interest was $31,063.

 

PPP Loans

 

In February 2021, we received an additional $261,164 in PPP loans under the CARES Act. This loan bears interest at a rate of 1% per annum and matures in April 2025. As of March 31, 2023, the outstanding balance of this loan was $197,457 and accrued interest was $8,923.

 

Contractual Obligations

 

Our principal commitments consist mostly of obligations under the loans described above and pricing/margin structures for products established with our clients. We do not have any purchase obligations with any suppliers.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Critical Accounting Policies

 

The preparation of our unaudited condensed consolidated financial statements requires our management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On a regular basis, we evaluate these estimates. These estimates are based on management’s historical industry experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from these estimates.

 

For a description of the accounting policies that, in management’s opinion, involve the most significant application of judgment or involve complex estimation and which could, if different judgment or estimates were made, materially affect our reported financial position, results of operations, or cash flows, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the Securities and Exchange Commission, or the SEC, on March 31, 2023.

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

Not applicable.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). Disclosure controls and procedures refer to controls and other procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

 

As required by Rule 13a-15(e) of the Exchange Act, our management has carried out an evaluation, with the participation and under the supervision of our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as of March 31, 2023. Based upon, and as of the date of this evaluation, our chief executive officer and chief financial officer determined that our disclosure controls and procedures were effective.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in our internal control over financial reporting or in any other factors that could significantly affect these controls during the three months ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

PART II

OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these, or other matters, may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.

 

ITEM 1A. RISK FACTORS.

 

Not applicable.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

We have not sold any equity securities during the three months ended March 31, 2023 that were not previously disclosed in a current report on Form 8-K that was filed during the quarter.

 

We did not repurchase any shares of our common stock during the three months ended March 31, 2023.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable.

 

ITEM 5. OTHER INFORMATION.

 

None.

 

 

ITEM 6. EXHIBITS.

 

Exhibit No.		Description
3.1		Articles of Incorporation of Smart for Life, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on April 13, 2023)
3.2		Certificate of Amendment to Articles of Incorporation of Smart for Life, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on April 28, 2023)
3.3		Certificate of Designation of Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed on April 13, 2023)
3.4		Bylaws of Smart for Life, Inc. (incorporated by reference to Exhibit 3.3 to the Current Report on Form 8-K filed on April 13, 2023)
4.1		Common Stock Purchase Warrant issued by Smart for Life, Inc. to Armistice Capital Master Fund Ltd. on May 5, 2023 (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-3 filed on May 5, 2023)
4.2		Placement Agent Common Stock Purchase Warrant issued by Smart for Life, Inc. to H.C. Wainwright & Co., LLC (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-3 filed on May 5, 2023)
4.3		Amended and Restated Common Stock Purchase Warrant issued by Smart for Life, Inc. to Anson East Master Fund LP on December 8, 2022 (incorporated by reference to Exhibit 4.11 to the Current Report on Form 8-K filed on December 9, 2022)
4.4		Amended and Restated Common Stock Purchase Warrant issued by Smart for Life, Inc. to Anson East Master Fund LP on December 8, 2022 (incorporated by reference to Exhibit 4.12 to the Current Report on Form 8-K filed on December 9, 2022)
4.5		Amended and Restated Common Stock Purchase Warrant issued by Smart for Life, Inc. to Anson Investments Master Fund LP on December 8, 2022 (incorporated by reference to Exhibit 4.13 to the Current Report on Form 8-K filed on December 9, 2022)
4.6		Amended and Restated Common Stock Purchase Warrant issued by Smart for Life, Inc. to Anson Investments Master Fund LP on December 8, 2022 (incorporated by reference to Exhibit 4.14 to the Current Report on Form 8-K filed on December 9, 2022)
4.7		Amended and Restated Common Stock Purchase Warrant issued by Smart for Life, Inc. to District 2 Capital Fund LP on December 8, 2022 (incorporated by reference to Exhibit 4.15 to the Current Report on Form 8-K filed on December 9, 2022)
4.8		Amended and Restated Common Stock Purchase Warrant issued by Smart for Life, Inc. to District 2 Capital Fund LP on December 8, 2022 (incorporated by reference to Exhibit 4.16 to the Current Report on Form 8-K filed on December 9, 2022)
4.9		Amended and Restated Common Stock Purchase Warrant issued by Smart for Life, Inc. to Ionic Ventures, LLC on December 8, 2022 (incorporated by reference to Exhibit 4.17 to the Current Report on Form 8-K filed on December 9, 2022)
4.10		Amended and Restated Common Stock Purchase Warrant issued by Smart for Life, Inc. to Ionic Ventures, LLC on December 8, 2022 (incorporated by reference to Exhibit 4.18 to the Current Report on Form 8-K filed on December 9, 2022)
4.11		Amended and Restated Common Stock Purchase Warrant issued by Smart for Life, Inc. to Sabby Volatility Warrant Master Fund Ltd. on December 8, 2022 (incorporated by reference to Exhibit 4.19 to the Current Report on Form 8-K filed on December 9, 2022)
4.12		Amended and Restated Common Stock Purchase Warrant issued by Smart for Life, Inc. to Sabby Volatility Warrant Master Fund Ltd. on December 8, 2022 (incorporated by reference to Exhibit 4.20 to the Current Report on Form 8-K filed on December 9, 2022)
4.13		Common Stock Purchase Warrant issued by Smart for Life, Inc. to Dawson James Securities, Inc. on December 8, 2022 (incorporated by reference to Exhibit 4.21 to the Current Report on Form 8-K filed on December 9, 2022)
4.14		Common Stock Purchase Warrant issued by Smart for Life, Inc. to Dawson James Securities, Inc. on December 8, 2022 (incorporated by reference to Exhibit 4.22 to the Current Report on Form 8-K filed on December 9, 2022)

  

 

4.15		Common Stock Purchase Warrant issued by Smart for Life, Inc. to Robert D. Keyser, Jr. on December 8, 2022 (incorporated by reference to Exhibit 4.23 to the Current Report on Form 8-K filed on December 9, 2022)
4.16		Common Stock Purchase Warrant issued by Smart for Life, Inc. to James Hopkins on December 8, 2022 (incorporated by reference to Exhibit 4.24 to the Current Report on Form 8-K filed on December 9, 2022)
4.17		Warrant Agent Agreement, dated February 16, 2022, between Smart for Life, Inc. and VStock Transfer, LLC and Forms of Warrants (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed on February 23, 2022)
4.18		Warrant issued by Smart for Life, Inc. to Joseph Xiras on January 13, 2022 (incorporated by reference to Exhibit 4.21 to Amendment No. 2 to Registration Statement on Form S-1/A filed on January 21, 2022)
4.19		Warrant issued by Smart for Life, Inc. to Leonite Fund I, LP on January 13, 2022 (incorporated by reference to Exhibit 4.22 to Amendment No. 2 to Registration Statement on Form S-1/A filed on January 21, 2022)
4.20		Warrant issued by Smart for Life, Inc. to Laurie Rosenthal on January 7, 2022 (incorporated by reference to Exhibit 4.20 to Amendment No. 2 to Registration Statement on Form S-1/A filed on January 21, 2022)
4.21		Warrant issued by Smart for Life, Inc. to Robert Rein on January 3, 2022 (incorporated by reference to Exhibit 4.19 to Amendment No. 2 to Registration Statement on Form S-1/A filed on January 21, 2022)
4.22		Warrant issued by Smart for Life, Inc. to Thomas L Calkins II and Diane M Calkins JTIC on December 27, 2021 (incorporated by reference to Exhibit 4.18 to Amendment No. 2 to Registration Statement on Form S-1/A filed on January 21, 2022)
4.23		Warrant issued by Smart for Life, Inc. to Ryan Hazel on December 23, 2021 (incorporated by reference to Exhibit 4.17 to Amendment No. 2 to Registration Statement on Form S-1/A filed on January 21, 2022)
4.24		Amended and Restated Warrant issued by Smart for Life, Inc. to Dawson James Securities, Inc. on February 1, 2022 (incorporated by reference to Exhibit 4.25 to Amendment No. 3 to Registration Statement on Form S-1/A filed on February 2, 2022)
4.25		Warrant issued by Smart for Life, Inc. to Dawson James Securities, Inc. on July 1, 2021 (incorporated by reference to Exhibit 4.23 to Amendment No. 3 to Registration Statement on Form S-1/A filed on February 2, 2022)
4.26		Warrant issued by Smart for Life, Inc. to Dawson James Securities, Inc. on July 1, 2021 (incorporated by reference to Exhibit 4.24 to Amendment No. 3 to Registration Statement on Form S-1/A filed on February 2, 2022)
4.27		Common Stock Purchase Warrant issued by Smart for Life, Inc. to Peah Capital, LLC on December 18, 2020 (incorporated by reference to Exhibit 4.14 to the Registration Statement on Form S-1 filed on December 16, 2021)
4.28		Amendment No 1 to Common Stock Purchase Warrant, dated June 30, 2021, between Smart for Life, Inc.  and Peah Capital, LLC (incorporated by reference to Exhibit 4.15 to the Registration Statement on Form S-1 filed on December 16, 2021)
31.1*		Certifications of Principal Executive Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*		Certifications of Principal Financial and Accounting Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**		Certifications of Principal Executive Officer furnished pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**		Certifications of Principal Financial and Accounting Officer furnished pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

*	Filed herewith

**	Furnished herewith

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: May 22, 2023	SMART FOR LIFE, INC.
	/s/ Darren C. Minton
	Name: Darren C. Minton
	Title: Chief Executive Officer
	(Principal Executive Officer)
	/s/ Alan B. Bergman
	Name: Alan B. Bergman
	Title: Chief Financial Officer
	(Principal Financial and Accounting Officer)

 

 

43